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ABSTRACT 
 
NEUROENDOCRINE SIGNALS ACT IN THE HINDBRAIN AND MESOPONTINE 
TEGMENTUM TO CONTROL ENERGY BALANCE 
David Joseph Reiner 
Matthew R. Hayes, Ph.D. 
 
 With the high prevalence of overweight and obese people in the United States, 
understanding the endogenous systems that control energy balance is of clinical 
significance. Given that obesity is driven, in part, by excessive intake of calories, it is 
critical to understand how food intake is controlled, with the goal of improving 
pharmacotherapies to treat obesity. A variety of peripherally and centrally-derived 
neuroendocrine signals are released following ingestion and act in distributed nuclei 
throughout the brain to control energy balance. The contribution of particular nuclei and 
the specific cell types within those nuclei that impact energy balance control requires 
further investigation. This dissertation focuses on novel mechanisms of two 
anorexogenic hormones, glucagon-like peptide-1 (GLP-1) and amylin, for energy 
balance control. Given that glutamatergic signaling mediates the intake suppressive 
effects of GLP-1 and that astrocytes are key modulators of synaptic glutamate levels, I 
hypothesize that GLP-1 receptors (GLP-1R) are expressed on astrocytes within the 
nucleus tractus solitarius (NTS), a feeding relevant nucleus, and contribute to energy 
balance control. Furthermore, neurons within the NTS produce GLP-1 and project widely 
throughout the brain. Given that the lateral dorsal tegmental nucleus (LDTg), an 
understudied region in energy balance control, receives projections from the NTS and 
expresses the GLP-1R, I hypothesize that GLP-1R signaling in the LDTg regulates 
 
vi 
	
energy balance control. Traditionally believed to act in the area postrema, the hormone 
amylin has recently been shown to act in mesolimbic regions to control energy balance, 
findings that have broadened the perspectives of CNS amylin action. Given that the 
LDTg binds amylin and receives and send projections to mesolimbic sites, I 
hypothesized that the amylin receptor signaling in the LDTg modulates energy balance. 
Collectively, the data presented in this dissertation broaden our understanding of the 
central nervous system (CNS) action of neuroendocrine signals for energy balance 
control, in terms of both cell- and nuclei-specificity, providing greater insight into potential 
targets for the developing improved pharmacotherapies to treat obesity. 
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CHAPTER 1: INTRODUCTION 
 The prevalence of obesity in the United States has increased over the past 
several decades, with currently 36.5% of adults classified as obese by Body Mass Index 
(BMI) (Ogden et al., 2015).  Obesity is characterized by a chronic state of positive 
energy balance and weight gain, driven in part by caloric intake beyond metabolic need 
(Narayanan et al., 2010; Kenny, 2011; Grill and Hayes, 2012). This hyperphagia typically 
occurs in times of energy abundance, largely because of non-homeostatic feeding of 
highly caloric and rewarding palatable foods (Lutter and Nestler, 2009; Halford et al., 
2010). However, the causes of and therapeutic treatment strategies to prevent this 
chronic hyperphagia remain unclear. As obesity is co-morbid with heart disease, stroke, 
diabetes, and cancer, each obese patient pays on average an additional $1,429 annually 
compared to a normal weight age-matched patient (Finkelstein et al., 2009). In addition, 
over $147 billion in annual direct medical care is spent on obese patients, placing an 
extreme burden on the US health care system (Finkelstein et al., 2009). It is therefore 
important to develop effective treatments for obesity. However, individuals attempting to 
lose weight by diet and exercise often fail, and bariatric surgery is invasive and 
expensive. Pharmacotherapy may be a more effective approach to treat obesity, but 
current non-invasive therapeutic pharmacological agents produce only a ~5-10% 
reduction in weight loss and are limited by adverse side effects and restricted use with 
certain co-morbidities (Cooke and Bloom, 2006; Dunican et al., 2010; Gadde and 
Pritham Raj, 2017). By examining the endogenous systems that govern energy balance, 
novel and specific therapeutic targets can be identified for obesity treatment. 
 Energy balance in mammals is controlled by a complex set of neuroendocrine 
signals that act together to regulate energy intake and expenditure (Grill and Hayes, 
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2012). These include neural signals, such as gut-brain communication via the vagus 
nerve, as well as numerous hormones produced peripherally and centrally. Many of 
these hormones, such as glucagon-like peptide-1 (GLP-1) (Hayes et al., 2010; Hayes, 
2012; Hayes et al., 2014a) and amylin (Mack et al., 2007; Mack et al., 2010; Mietlicki-
Baase et al., 2013b), affect food intake and the incentive value of food by binding to their 
individual receptors on vagal afferents or directly in the central nervous system (CNS), 
ultimately leading to alterations in physiology and behavior (Berthoud, 2002; Grill and 
Kaplan, 2002; Lutz, 2006; Grill and Hayes, 2012; Hayes et al., 2014a; Mietlicki-Baase 
and Hayes, 2014; Hayes and Schmidt, 2016; Kanoski et al., 2016; Mietlicki-Baase, 
2016). While these signals are processed by a distributed set of CNS structures, the 
contribution of particular nuclei and the specific cell types within those nuclei that impact 
energy balance control still remain largely unknown. It is therefore crucial to understand 
the CNS circuitry engaged by these energy status signals to modulate energy balance 
and the rewarding value of food, as this may enable us to develop improved therapeutic 
targets for obesity.  
This dissertation focuses on examining novel mechanisms governing energy 
balance control. Experiments focus on the role of astrocytes, an often-overlooked 
regulator of synaptic neurotransmission, in energy balance control. Cell-type-specific 
effects (e.g. neurons vs. astrocytes) of GLP-1 receptor (GLP-1R) signaling are 
investigated in the context of mediating energy balance control. Further studies analyze 
the individual roles of GLP-1 and amylin for energy balance control in an understudied 
brain region for motivated behaviors, the lateral dorsal tegmental nucleus (LDTg). 
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Astrocytes: A general overview 
“What functional significance can be attributed to the neuroglia? Unfortunately, the 
present state of science does not allow to answer the important question but through 
more or less rational conjectures. When facing this problem, the physiologist is totally 
disarmed for lack of methods.” Santiago Ramon y Cajal, 1899, Textura del Sistema 
Nervioso del Hombre y de los Vertebrados. 
 
 First termed neuroglia, glia were first described by Rudolf Virchow in 1846 as the 
“connective tissue” or “cement” of the brain [see (Garcia-Marin et al., 2007) for review]. 
However, in comparison to neurons, glia have historically been neglected in 
neuroscience as glia are not electrically excitable. Currently, while the number of 
research articles on the role of neurons is still extremely high compared to glia, we know 
that there are nearly as many neurons as glial cells in the brain and over eight types of 
glia have been identified, including astrocytes (Garcia-Marin et al., 2007; Herculano-
Houzel, 2014; von Bartheld et al., 2016). Named for their star-like shape, astrocytes 
were long thought of as the “glue” of the brain and silent partners in brain function and 
plasticity (Garcia-Marin et al., 2007). Over one hundred years ago and largely based off 
evidence from static images of astrocyte staining, Santiago Ramon y Cajal proposed 
physiological roles for astrocytes in brain function as well as physiology and behavior, 
including the potential involvement of astrocytes in attention and sleep/wake states [see 
(Garcia-Marin et al., 2007; Navarrete and Araque, 2014) for review]. With the emergence 
of advanced techniques to study astrocytes, these proposals have largely been 
confirmed in recent years. Indeed, findings have illuminated the diverse roles astrocytes 
play in synaptic activity, forming what is termed a tripartite synapse, consisting of a 
presynaptic and a postsynaptic neuron and an astrocyte (Nedergaard et al., 2003; 
Ransom et al., 2003; Barres, 2008; Eroglu and Barres, 2010; Clarke and Barres, 2013; 
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Robinson and Jackson, 2016). Astrocytes have a critical role in regulating synaptic 
activity and express receptors for a variety of neurotransmitters. Upon neurochemical 
stimulation of astrocytes, intracellular calcium levels increase and astrocytes can release 
gliotransmitters (Nedergaard et al., 2003; Ransom et al., 2003; Halassa et al., 2007; 
Barres, 2008; Eroglu and Barres, 2010; Clarke and Barres, 2013; Robinson and 
Jackson, 2016). Astrocytes are also key modulators of synaptic and extrasynaptic 
glutamate levels through expression of glutamate transporters such as the glutamate 
transporter-1 (GLT-1) and the glutamate-aspartate transporter (GLAST) [see (Perego et 
al., 2000; Rimmele and Rosenberg, 2016) for review]. Recently, these cellular and 
synaptic functions of astrocytes have been shown to be relevant for physiology and 
behavior (Florian et al., 2011; Bull et al., 2014; Fields et al., 2014; Scofield and Kalivas, 
2014; Scofield et al., 2015), including an understudied but potentially important role in 
energy balance control (Yi et al., 2011; Chowen et al., 2016; Leloup et al., 2016; 
Argente-Arizon et al., 2017).  
Astrocytes: Roles in energy balance 
Research has established that astrocytes sense a variety of nutrients and 
hormones from the blood and play dynamic roles in cellular energy homeostasis and 
energy balance control more broadly (Yi et al., 2011; Chowen et al., 2016; Leloup et al., 
2016; Argente-Arizon et al., 2017). One of the first discoveries was that hypothalamic 
astrocytes express glucose transporters 1 and 2 (GLUT1 and GLUT2) and thereby have 
an important function in glycemic regulation, including sensing blood glucose, supplying 
glucose to nearby neurons, and ultimately controlling food intake [see (Leloup et al., 
2016) for review].  
 
5 
	
Astrocytes contribute to synaptic and micro-circuit level plasticity in the 
development and maintenance of obesity and respond to neuropeptides [see (Dorfman 
and Thaler, 2015; Chowen et al., 2016) for review]. Obesity can be modeled by exposing 
animals to a high fat diet, which leads to hyperphagia, peripheral and central 
inflammatory responses and weight gain [see (Madsen et al., 2010; Dorfman and Thaler, 
2015; Chowen et al., 2016; Guillemot-Legris and Muccioli, 2017) for review]. In the brain, 
increases in astrocyte number and changes in morphology, termed astrogliosis or 
gliosis, are hallmarks of inflammation and are caused by high fat diet exposure (Chowen 
et al., 2016). Changes in the number or morphology of astrocytes can lead to changes in 
cellular communication, nutrient and hormonal sensing from the blood, and release of 
cytokines associated with inflammation and oxidative stress (Chowen et al., 2016; 
Argente-Arizon et al., 2017). These changes may be protective following acute ingestion 
of a high fat diet, but chronic consumption of a high fat diet leads to maladaptive 
alterations in astrocyte expression and morphology, thereby perpetuating the overweight 
or obese state (Chowen et al., 2016; Argente-Arizon et al., 2017). However, the 
contribution of astrocytes to energy balance control has been examined almost 
exclusively in the hypothalamus, disregarding the potential contribution of astrocytes in 
other distributed brain regions relevant to energy balance control (Guillemot-Legris and 
Muccioli, 2017). Indeed, the role of numerous energy balance relevant hormones and 
neurotransmitters for astrocyte-mediated energy balance control requires further 
investigation. It is therefore crucial to understand, both in the “normal” lean state and in 
the obese state, the specific hormones or neuropeptides to which astrocytes respond, 
how astrocytes interact with neurons to control energy balance, and to identify areas of 
the brain in which astrocytes contribute to energy balance control. 
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The nucleus tractus solitarius (NTS) of the caudal brainstem 
 The importance of the caudal brainstem for feeding and energy balance control is 
highlighted by experiments done by Grill and colleagues dating back to the 1970s in 
which consummatory feeding was examined in chronic decerebrate rats, whose 
hindbrain and forebrain have been surgically separated (Grill and Norgren, 1978c, b, a; 
Flynn and Grill, 1988; Grill and Smith, 1988; Mark et al., 1988; Grill and Kaplan, 2001). 
Collectively, these studies showed that chronic decerebrate rats respond appropriately 
and similarly to intact rats in taste reactivity and single meal tests, suggesting that the 
caudal brainstem is sufficient for controlling ingestive behavior during short-term testing 
(Grill and Norgren, 1978c, b, a; Flynn and Grill, 1988; Grill and Smith, 1988; Mark et al., 
1988; Grill and Kaplan, 2001). However, chronic decerebrate rats cannot engage in 
appetitive behaviors aimed at food procurement and do not appropriately compensate in 
meal size following food deprivation, indicating that the brainstem in isolation from the 
forebrain is not sufficient for the modulation of ingestive behavior over the long-term 
(Grill and Norgren, 1978c, b, a; Flynn and Grill, 1988; Grill and Smith, 1988; Mark et al., 
1988; Grill and Kaplan, 2001). Together, these data underscore the importance of the 
hindbrain in integrating taste and gastrointestinal signals for acute control of meal size, 
but also emphasize the importance of hindbrain-forebrain communication in responding 
to the neuroendocrine signals that control the motivational aspects of feeding and long-
term food intake (Grill and Kaplan, 2001). 
 The nucleus tractus solitarius (NTS) of the caudal brainstem is a critical nucleus 
in the regulation of energy balance. The NTS receives vagally-mediated gastrointestinal 
(GI) satiation signals and blood-borne energy status signals (Grill and Hayes, 2009, 
2012). During ingestion, the GI tract senses chemical and nutritive properties of the 
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ingested food, stimulating the release of a number of gut peptides and neurotransmitters 
that can be released into the bloodstream or can bind to receptors on vagal sensory 
afferents, which first synapse in the NTS (Grill and Hayes, 2009, 2012). In addition, the 
NTS expresses receptors for a wide variety of peripherally and centrally-derived 
peptides and neurotransmitters (Grill and Hayes, 2009, 2012). The NTS therefore 
integrates diverse sensory information from the GI tract with circulating and centrally-
derived neuroendocrine signals, and sends projections to other distributed brain areas to 
control feeding behavior and other aspects of energy balance control (Grill and Hayes, 
2009, 2012). 
The glucagon-like peptide-1 system in the NTS 
 Within the NTS, the GLP-1 system stands out for its biological and physiological 
relevance for energy balance control, as well as its clinical relevance for diabetes and 
obesity treatment. GLP-1 is an anorectic hormone released peripherally from intestinal L 
cells following meal initiation and centrally from preproglucagon (PPG) neurons in the 
NTS following a variety of stimuli, including gastric distension (Vrang et al., 2003; Grill 
and Hayes, 2012; Hayes et al., 2014a). Given that GLP-1 is rapidly degraded by the 
enzyme dipeptidyl peptidase-IV (DPP-IV), peripheral GLP-1 is thought to act primarily in 
a paracrine fashion on adjacent vagal afferents. In contrast, central GLP-1 is thought to 
act primarily as a neuropeptide, as PPG neurons project locally within the NTS and 
widely throughout the CNS (Rinaman, 2010; Dossat et al., 2011; Alhadeff et al., 2012; 
Kanoski et al., 2016). Therefore, centrally-produced GLP-1 is thought to be the main 
source of activation for GLP-1 receptor (GLP-1R) populations throughout the CNS, 
either through direct projections of PPG neurons or through volume transmission into the 
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cerebral spinal fluid (CSF) (Dossat et al., 2011; Alhadeff et al., 2012; Hsu et al., 2015; 
Kanoski et al., 2016).  
 PPG neurons in the NTS project widely throughout the brain, including but not 
limited to, mesolimbic regions such as the ventral tegmental area (VTA) and nucleus 
accumbens (NAc), as well as hypothalamic structures (Vrang et al., 2007; Dossat et al., 
2011; Alhadeff et al., 2012; Dossat et al., 2013; Mietlicki-Baase et al., 2013a; Mietlicki-
Baase et al., 2014; Burmeister et al., 2017). As PPG neurons are also glutamatergic 
(Zheng et al., 2014), it is believed that activation of PPG neurons (e.g. after gastric 
distension) would result in release of GLP-1 and/or glutamate release in downstream 
projection targets (either within the NTS or other CNS regions), though the precise 
dynamics of this release are not known. 
Glucagon-like peptide-1 receptor signaling in the NTS 
 Within the NTS, GLP-1R signaling has been shown to modulate energy balance 
control. Direct NTS microinjection of the long-acting GLP-1R agonist exendin-4 (Ex-4) 
decreases food intake (Hayes et al., 2011b). In addition, blockade of NTS GLP-1Rs via 
microinjection of the competitive GLP-1R antagonist exendin-(9-39) (Ex-9) increases 
feeding and attenuates the intake suppression following gastric distension (Hayes et al., 
2009). NTS GLP-1R activation also has a number of other feeding/energy balance-
relevant effects, such as decreased intake of a palatable high fat diet, reduced 
conditioned place preference (CPP) for a palatable food, and lower progressive ratio 
responding for sucrose (a measure of motivation) (Alhadeff and Grill, 2014; Richard et 
al., 2015). Chronic knockdown of NTS GLP-1R results in increased chow intake and 
meal size as well as increased operant responding for sucrose on fixed ratio and 
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progressive ratio schedules of reinforcement (Alhadeff et al., 2016). Collectively, these 
data establish important pharmacological and physiological roles for NTS GLP-1R 
signaling in food intake control and motivated behavior. However, the specific cell types 
that bind GLP-1 and clinically relevant long-acting GLP-1R agonists within the NTS and 
the CNS in general have yet to be systemically evaluated. 
 GLP-1R activation decreases food intake at least in part through an α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-receptor dependent process, 
suggesting that glutamate signaling following GLP-1R activation plays an important role 
in food intake suppression (Mietlicki-Baase et al., 2013a; Mietlicki-Baase et al., 2014). 
GLP-1Rs are G-protein coupled receptors (GPCRs) coupled to Gs, and activation of 
GLP-1R leads to increased intracellular calcium and cAMP, PKA and MAPK activation, 
and downregulation of AMPK (Perfetti and Merkel, 2000; Gomez et al., 2002; Hayes et 
al., 2011b). However, a limitation of previous studies examining CNS GLP-1R signaling 
from hindbrain tissue is that one cannot distinguish between CNS cell types with results 
from tissue lysates. In addition, GLP-1Rs are expressed widely throughout the CNS 
(Merchenthaler et al., 1999) and in recent years GLP-1R signaling in several nuclei has 
been shown to regulate energy balance control (Alhadeff et al., 2012; Mietlicki-Baase et 
al., 2013a; Alhadeff et al., 2014; Alhadeff and Grill, 2014; Mietlicki-Baase et al., 2014; 
Secher et al., 2014; Hsu et al., 2015; Alhadeff et al., 2016). Collectively, these data 
highlight the importance of further examination of the specific cell types that bind GLP-1 
and long acting GLP-1R agonists, the intracellular signaling cascades engaged within 
these cells, and the specific brain regions involved in GLP-1R-mediated control of 
energy balance. 
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 Though PPG neurons in the NTS have been shown to project to mesolimbic and 
hypothalamic nuclei and exert control over energy balance (Larsen et al., 1997; Dossat 
et al., 2011; Alhadeff et al., 2012; Mietlicki-Baase et al., 2013a; Mietlicki-Baase et al., 
2014; Hsu et al., 2015; Kanoski et al., 2016; Schmidt et al., 2016; Terrill et al., 2016), 
other nuclei throughout the CNS also express GLP-1R (Merchenthaler et al., 1999) but 
are under-investigated for their role in energy balance control. One of these nuclei is the 
lateral dorsal tegmental nucleus (LDTg), which integrates information from nuclei 
throughout the neuraxis to modulate motivated behavior (Cornwall et al., 1990; Schmidt 
et al., 2009; Shabani et al., 2010; Lammel et al., 2012; Shinohara et al., 2014; Steidl et 
al., 2015; Steidl et al., 2017). The LDTg is also critically positioned to integrate energy 
balance information throughout the brain (Cornwall et al., 1990) and thus may potentially 
mediate energy balance. 
The lateral dorsal tegmental nucleus: an understudied hub potentially mediating 
motivated behavior and energy balance 
 Given that the control of energy balance is distributed throughout the CNS (Grill 
and Kaplan, 2002; Grill and Hayes, 2012), a deeper understanding of the relevant CNS 
circuitry and how it responds to and integrates energy balance signals to control food 
intake and body weight is needed. The LDTg of the mesopontine tegmentum represents 
an understudied hub that may mediate motivated behavior and energy balance. 
Historically, lesion studies established a role for the LDTg in motivated behavior (Blaha 
et al., 1996; Laviolette et al., 2000; Forster et al., 2002b; Alderson et al., 2005; Dobbs 
and Cunningham, 2014; Steidl et al., 2015) and recently more specific techniques have 
clarified these roles of the LDTg in motivated behavior and energy balance regulation 
(Omelchenko and Sesack, 2005; Lodge and Grace, 2006; Schmidt et al., 2009; Dickson 
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et al., 2010; Shabani et al., 2010; Dickson et al., 2011; Jerlhag et al., 2012; Lammel et 
al., 2012; Shinohara et al., 2014; Steidl et al., 2015; Steidl et al., 2017). The LDTg also 
expresses receptors for a variety of energy balance-relevant hormones, including GLP-
1, amylin, ghrelin, oxytocin, orexin and PYY (Sexton et al., 1994; Merchenthaler et al., 
1999; Parker and Herzog, 1999; Greco and Shiromani, 2001; Gould and Zingg, 2003; 
Dickson et al., 2011; Cabral et al., 2013). Indeed, the neuroanatomical connectivity of 
the LDTg with a variety of key feeding-relevant CNS nuclei and the expression of 
receptors for various feeding-related signals underscore the potential relevance of the 
LDTg as a hub for energy balance control. 
Neuroanatomy of the LDTg: projection pathways and cellular phenotypes 
 Inputs to the LDTg include nuclei relevant for motivated behavior and energy 
balance such as the prefrontal cortex, lateral hypothalamus, lateral habenula, 
interpeduncular nucleus, VTA, substantia nigra pars compacta, parabrachial nucleus, 
and NTS (Satoh and Fibiger, 1986; Cornwall et al., 1990). The majority of these 
projections are from the ipsilateral region, but retrograde labeling from the lateral 
habenula, interpenducular nucleus, and NTS was found to be bilateral (Cornwall et al., 
1990). Importantly, the NTS neurons that project to the LDTg are found at the level of 
the obex (Cornwall et al., 1990), which is the same rostral-caudal location of PPG 
neurons (Han et al., 1986; Larsen et al., 1997), suggesting that NTS PPG neurons may 
project to the LDTg. The specific neurochemical and neuropeptide phenotypes of most 
of these inputs require further investigation. 
 Efferent projection targets from the LDTg include the prefrontal cortex, 
hippocampus, lateral septum, thalamic nuclei, lateral habenula, lateral hypothalamus, 
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substantia nigra pars compacta, VTA, interpeduncular nucleus, dorsal and medial raphe, 
pedunculopontine tegmental nucleus, parabrachial nucleus, and the NTS (Satoh and 
Fibiger, 1986; Cornwall et al., 1990). Again, the majority of these projections are 
ipsilateral, but anterograde labeling in the prefrontal cortex, lateral septum, thalamic 
nuclei, lateral habenula, and VTA is bilateral (Cornwall et al., 1990). Among these 
outputs, the projection pathway from the LDTg to VTA has been the focus of a majority 
of scientific investigation on the LDTg (detailed below). 
 Three distinct subpopulations of LDTg neurons have been identified based on 
their neurochemical phenotype. Around 22% of LDTg neurons express choline 
acetyltransferase (ChAT) and are cholinergic, while around 38% of LDTg neurons 
express the glutamatergic marker vesicular glutamate transporter (vGlut2) and 40% of 
LDTg neurons express the gamma-aminobutyric acid (GABA)-ergic marker glutamic acid 
decarboxylase (GAD) (Wang and Morales, 2009). Importantly, only a small percentage 
of cholinergic neurons express vGlut2 or GAD, suggesting that these neuronal subtypes 
are predominately distinct populations of cells that are distributed throughout the LDTg 
(Wang and Morales, 2009). Though increasing evidence suggests a role for LDTg 
modulation of VTA dopaminergic transmission (detailed below), LDTg efferents to other 
nuclei that may play roles in motivated behavior and energy balance require further 
investigation. 
The LDTg: discoveries with lesion studies 
 Specific lesions to the LDTg result in decreased spontaneous locomotor activity, 
blunted locomotor activity in response to amphetamine, methamphetamine, 
scopolamine, nicotine, and morphine, and increased latency to self-administer cocaine 
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(Blaha et al., 1996; Laviolette et al., 2000; Forster et al., 2002b; Alderson et al., 2005; 
Dobbs and Cunningham, 2014; Steidl et al., 2015). LDTg lesions also attenuate 
dopamine efflux in the NAc following VTA acetylcholinesterase inhibition (Blaha et al., 
1996). Electrical stimulation of the LDTg activates VTA acetylcholine and glutamate 
receptors, leading to an increase in dopamine release in the NAc (Forster and Blaha, 
2000; Forster et al., 2002a; Lester et al., 2010). Collectively, these previous studies 
established a role for the LDTg in modulating the mesolimbic dopamine system and 
have led the way for more targeted techniques that examine the specific mechanisms 
underlying how the LDTg modulates the dopamine system in motivated behaviors. 
The LDTg: modulation of VTA dopaminergic system 
 The LDTg is required for burst firing of VTA dopamine neurons (Lodge and 
Grace, 2006). Neuroanatomical techniques show that the LDTg neurons synapse on 
NAc-projecting and prefrontal cortex-projecting VTA dopamine neurons as well as VTA 
GABA neurons, suggesting that the LDTg may have bi-directional control over dopamine 
release in the NAc and prefrontal cortex (Omelchenko and Sesack, 2005). However, the 
precise neurochemical phenotype of these projections needs to be further investigated, 
in terms of the percentage of LDTg cholinergic, glutamatergic, and GABAergic neurons 
that synapse onto each VTA neuronal subtype.  
 Behavioral techniques show that the LDTg is important for motivated behaviors, 
including drug-related behaviors. Hyperpolarizing LDTg neurons with carbachol prevents 
CPP for cocaine while pharmacological blockade of LDTg AMPA and N-methyl-D-
aspartate (NMDA) receptors attenuates CPP for cocaine (Shinohara et al., 2014). In 
addition, rats receiving a microinjection of a muscarinic acetylcholine 2 receptor 
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antagonist in the LDTg show decreased responding for cocaine on progressive ratio 
schedules of reinforcement (Shabani et al., 2010). The LDTg also plays a role in cocaine 
seeking as AMPA receptor blockade in the LDTg attenuates cocaine priming-induced 
reinstatement (Schmidt et al., 2009). Current techniques employing optogenetics show 
that optogenetic excitation of the LDTg-to-VTA glutamatergic and cholinergic projection 
elicits a CPP (Lammel et al., 2012; Steidl et al., 2017). Furthermore, rats lever press for 
photostimulation of VTA-projecting LDTg axons (Steidl and Veverka, 2015). Collectively, 
research has established that the LDTg modulates the dopaminergic system, which has 
important implications in motivated behavior. These studies have focused on drug-
related behaviors, but given the overlap in neural circuitry underlying drug abuse and 
feeding (Narayanan et al., 2010; DiLeone et al., 2012), this strongly suggests that the 
LDTg may be critical for the control of energy balance. 
The LDTg: neuroendocrine signals 
The LDTg expresses receptors for a variety of energy balance-relevant signals, 
including GLP-1, amylin, ghrelin, oxytocin, orexin and PYY (Sexton et al., 1994; 
Merchenthaler et al., 1999; Parker and Herzog, 1999; Greco and Shiromani, 2001; 
Gould and Zingg, 2003; Dickson et al., 2011; Cabral et al., 2013). Among these signals, 
ghrelin’s action in the LDTg has been investigated to the greatest extent. Ghrelin 
administration into the LDTg increases acetylcholine release in the VTA, dopamine 
release in the nucleus accumbens, and ultimately food intake (Jerlhag et al., 2007; 
Dickson et al., 2010; Dickson et al., 2011; Jerlhag et al., 2012). These data suggest that 
the LDTg can respond to ghrelin to control energy balance. However, whether other 
neuroendocrine signals act in the LDTg to regulate energy balance and how this might 
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impact downstream activity in the VTA or other LDTg projection targets requires further 
investigation. Given that the LDTg receives projections from the NTS at the level of the 
obex (the same rostral-caudal level of PPG neurons) and the LDTg expresses GLP-1R 
mRNA (Cornwall et al., 1990; Merchenthaler et al., 1999), I hypothesize that GLP-1R 
signaling in the LDTg modulates energy balance (see Figure 1.1).  
It is crucial to examine CNS sites such as the LDTg that express a variety of 
neuroendocrine receptors and therefore potentially respond to and integrate a number of 
energy status signals. The LDTg binds amylin (Sexton et al., 1994), which is a 
pancreatic and centrally-derived anorectic hormone considered to be a promising target 
for obesity treatment (Aronne et al., 2007; Dunican et al., 2010; Singh-Franco et al., 
2011; Hay et al., 2015; Mietlicki-Baase, 2016). Though amylin is traditionally thought to 
act in the area postrema (Lutz et al., 1998b; Lutz et al., 2001; Lutz, 2010b, a; Potes and 
Lutz, 2010; Potes et al., 2010; Potes et al., 2012; Roth et al., 2012), recent data has 
highlighted a broader role for amylin’s action in the CNS to regulate energy balance with 
action in the VTA and NAc (Mietlicki-Baase et al., 2013b; Baisley and Baldo, 2014; 
Mietlicki-Baase et al., 2015b) and has shown that amylin can interact with other feeding 
related hormones (Lutz, 2013). Given that the LDTg binds amylin and projects to the 
VTA (Cornwall et al., 1990; Sexton et al., 1994), I hypothesize that amylin receptor 
signaling in the LDTg modulates energy balance and motivated behavior (see Figure 
1.1). 
Overview of dissertation 
 Given that energy balance control is distributed throughout the CNS and 
peripherally- or centrally-derived neuroendocrine signals can act at nuclei throughout the 
 
16 
	
brain [see (Grill and Kaplan, 2002; Grill and Hayes, 2012) for review], it is critical to 
examine the specific nuclei and cell types that are activated by these neuroendocrine 
signals and clinically relevant analogs. As GLP-1 and amylin regulate energy balance 
and are of clinical relevance, this thesis dissertation will investigate the cell specificity of 
GLP-1R signaling in the NTS for energy balance control and the LDTg as an 
understudied hub mediating energy balance via GLP-1 and amylin.  
 Recent attention has focused on the role of glutamatergic signaling in mediating 
the hypophagic effects of central GLP-1R activation (Hisadome et al., 2011; Mietlicki-
Baase et al., 2013a; Mietlicki-Baase et al., 2014). Surprisingly, the literature has 
overlooked the potential contribution of astrocytes, a key cell population that regulates 
synaptic glutamate levels (Perego et al., 2000; Rimmele and Rosenberg, 2016). Data 
have shown that astrocytes within the CNS express GLP-1Rs, though this has not been 
examined in the context of energy balance (Chowen et al., 1999; Iwai et al., 2006; 
Kobayashi et al., 2013). In Chapter 2, I test the hypothesis that GLP-1Rs are expressed 
on astrocytes in the NTS and are relevant for energy balance control.  
 Projections from the NTS to the LDTg are understudied, particularly in the 
context of GLP-1 signaling. Given that the NTS produces GLP-1 and the LDTg 
expresses GLP-1R mRNA, there is strong rationale to evaluate the behavioral and 
physiological effects of GLP-1R activation in the LDTg (Cornwall et al., 1990; 
Merchenthaler et al., 1999). In Chapter 3, I test the hypothesis that GLP-1R signaling 
within the LDTg contributes to energy balance control by examining the pharmacological 
and physiological relevance of LDTg GLP-1Rs (see Figure 1.1). 
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 The LDTg also expresses receptors for other neuroendocrine signals, including 
the core component of the amylin receptor, the calcitonin receptor (Sexton et al., 1994). 
In Chapter 4, I therefore test the hypothesis that amylin receptor signaling the LDTg 
contributes to energy balance control by examining the pharmacological and 
physiological relevance of LDTg amylin receptors (see Figure 1.1). 
 The data presented in this dissertation provide evidence that NTS astrocytes 
express GLP-1Rs, are relevant for energy balance control, and that GLP-1 and amylin 
each act in the LDTg to modulate energy balance. Collectively, these data broaden our 
understanding of the CNS action of neuroendocrine signals for energy balance control, 
in terms of both cell- and nuclei-specificity, providing greater insight into possible targets 
for the developing improved pharmacotherapies to treat obesity. 
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Figure 1.1. The LDTg represents a potential hub mediating energy balance. The 
LDTg sends reciprocal projections to multiple nuclei of relevance to energy balance 
control, including but not limited to the lateral hypothalamus (LH), nucleus tractus 
soliatrius (NTS), parabrachial nucleus (PBN), prefrontal cortex (PFC), and ventral 
tegmental area (VTA) (Cornwall et al., 1990). The LDTg expresses the GLP-1R 
(Merchenthaler et al., 1999) and the core component of the amylin receptor (Sexton et 
al., 1994). We hypothesize that NTS PPG/GLP-1 neurons project directly to the LDTg to 
control feeding and that the pancreatic-derived hormone amylin controls energy balance, 
in part, by direct action in the LDTg. 
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Abstract 
  Astrocytes are well-established modulators of extracellular glutamate, but their 
direct influence on energy balance-relevant behaviors is largely understudied. As the 
anorectic effects of glucagon-like peptide-1 receptor (GLP-1R) agonists are partly 
mediated by central modulation of glutamatergic signaling, we tested the hypothesis that 
astrocytic GLP-1R signaling regulates energy balance in rats. Peripheral administration 
of a fluorophore-labeled GLP-1R agonist, exendin-4, localizes within astrocytes and 
neurons in the nucleus tractus solitarius (NTS), a hindbrain nucleus critical for energy 
balance control. This effect is GLP-1R-mediated, as uptake of systemically administered 
fluorophore-tagged exendin-4 was blocked by central pretreatment with the competitive 
GLP-1R antagonist exendin-(9-39). Ex vivo analyses show prolonged exendin-4-induced 
activation (live cell calcium signaling) of NTS astrocytes and neurons; these effects are 
also attenuated by exendin-(9-39), indicating mediation by the GLP-1R. In vitro analyses 
show that application of GLP-1R agonists increases cAMP in astrocytes. 
Immunohistochemical analyses reveal that endogenous GLP-1 axons form close 
synaptic apposition with NTS astrocytes. Finally, pharmacological inhibition of NTS 
astrocytes attenuates the anorectic and body weight-suppressive effects of intra-NTS 
GLP-1R activation. Collectively, data demonstrate a role for NTS astrocytic GLP-1R 
signaling in energy balance control. 
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Introduction 
The nucleus tractus solitarius (NTS) of the caudal brainstem is a critical nucleus 
in the regulation of energy balance. The NTS acts as a sensor for circulating 
neuroendocrine factors important for the control of food intake and is the first nucleus 
within the brain to receive and process vagally-mediated satiation signals arising from 
the gastrointestinal (GI) tract (Grill and Hayes, 2012). The NTS is therefore well-
positioned as a key hub to combine a variety of feeding-related signals, and to transmit 
this integrated information to downstream nuclei to influence overall energy balance 
control (Grill and Hayes, 2009).  Within the NTS, the incretin hormone glucagon-like 
peptide-1 (GLP-1) acts to control food intake and body weight (Grill and Hayes, 2012; 
Hayes et al., 2014a). Produced peripherally by intestinal L cells and centrally by 
preproglucagon (PPG) neurons within the caudal NTS, GLP-1 and GLP-1 receptor 
(GLP-1R) agonists suppress food intake and body weight through direct GLP-1R 
signaling in the NTS, as well as through action in other distributed nuclei in the brain 
(McMahon and Wellman, 1998; Grill and Hayes, 2009; Dossat et al., 2011; Alhadeff et 
al., 2012; Mietlicki-Baase et al., 2013a; Rupprecht et al., 2013; Alhadeff et al., 2014; 
Mietlicki-Baase et al., 2014; Secher et al., 2014; Hsu et al., 2015). However, the cellular 
and molecular mechanisms mediating the energy balance effects of GLP-1R activation 
remain largely under-investigated. GLP-1R agonists such as exendin-4 (Ex-4) and 
liraglutide are widely used in the treatment of type 2 diabetes mellitus (T2DM) (Hayes et 
al., 2014a), and liraglutide was recently approved by the FDA for the treatment of obesity 
(Tella and Rendell, 2015). These important medical applications of GLP-1R agonists 
highlight the urgent need to understand more fully the mechanisms by which GLP-1R 
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activation impacts physiology and behavior, including the control of feeding and body 
weight. 
Vagal afferents synapsing in the NTS, as well as NTS PPG neurons themselves, 
are glutamatergic (Ritter, 2004; Grill and Hayes, 2012; Zheng et al., 2014). Thus, recent 
attention has focused on the role of glutamatergic signaling in mediating the 
anorexigenic effects of central GLP-1R activation. In particular, several studies 
demonstrate a role for the ionotropic AMPA/kainate glutamate receptors (Hisadome et 
al., 2011; Mietlicki-Baase et al., 2013a; Mietlicki-Baase et al., 2014) as downstream 
mediators of the food intake- and body weight-suppressive effects of GLP-1R signaling 
within mid- and forebrain nuclei. Importantly, these reports also indicate that the relevant 
GLP-1Rs are located presynaptically to AMPA/kainate receptors and can influence 
presynaptic glutamate release (Acuna-Goycolea and van den Pol, 2004; Amato et al., 
2010; Hisadome et al., 2011; Mietlicki-Baase et al., 2013a; Mietlicki-Baase et al., 2014). 
However, to date, the ability of GLP-1R activation to affect energy balance via non-
neuronal modulation of synaptic glutamatergic signaling has not been systematically 
evaluated.  
Most studies of the central control of energy balance have focused on the actions 
of neurons, but astrocytes represent another key central nervous system (CNS) cell 
population that modulates glutamatergic neurotransmission, thereby potentially 
influencing behavior (Scofield and Kalivas, 2014; Yang et al., 2015). Indeed, glutamate 
is predominately cleared from the synapse by two subtypes of astrocytic glutamate 
reuptake transporters: glutamate transporter-1 (GLT-1) and glutamate aspartate 
transporter (GLAST) (Perego et al., 2000; Danbolt, 2001). Intriguingly, a small body of 
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literature suggests that astrocytes within the CNS express the GLP-1R (Chowen et al., 
1999; Iwai et al., 2006; Kobayashi et al., 2013), yet no studies have systemically 
examined its expression or behavioral relevance for energy balance control. As the NTS 
expresses GLP-1R (Hayes et al., 2010; Hayes, 2012) and is the first central site to 
receive and process within-meal vagally-mediated glutamatergic signals arising from the 
GI tract (Moran, 2006; Grill and Hayes, 2009), a combination of in vitro, ex vivo, and in 
vivo techniques was utilized to test the hypothesis that GLP-1R signaling in NTS 
astrocytes is functionally relevant for energy balance control.  
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Materials and Methods 
Animals 
Male Sprague-Dawley rats (320-420 g, Charles River) individually housed in hanging 
wire cages maintained at 23°C with a 12h light/12h dark cycle were used for the majority 
of these studies. For the live cell calcium imaging studies, male Long-Evans rats (250-
300 g, breeding colony at Pennington Biomedical Research Center) were used. All 
procedures were approved by Institutional Animal Care and Use Committees (University 
of Pennsylvania, University of Southern California, Pennington Biomedical Research 
Center) and were performed according to the guidelines determined by the National 
Institutes of Health. Rats had ad libitum access to rodent chow and water unless 
otherwise noted. 
Stereotaxic surgery 
 For behavioral experiments, rats were surgically implanted with cannula targeting 
either the medial NTS (mNTS) or 4th cerebroventricle (4th i.c.v.). Rats were anesthetized 
with an intramuscular injection of ketamine (90 mg/kg), xylazine (2.7 mg/kg), and 
acepromazine (0.64 mg/kg) and placed in a stereotaxic apparatus. Guide cannulas 
(Plastics One; 26-gauge) were implanted using the following coordinates: 4th i.c.v. 
(midline, 2.5 mm anterior to the occipital suture, internal cannula aimed 7.2 mm ventral 
to skull); mNTS (bilateral cannula; 1.0 mm posterior to occipital crest, ±0.5 mm lateral to 
midline, internal cannula aimed 8.7 mm ventral to skull). Bone screws and dental cement 
adhered the cannula to the skull surface. Animals were treated with analgesia (2 mg/kg 
meloxicam, s.c.) and allowed one week to recover. Behavioral testing began ~14 days 
after surgery.  
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Fourth i.c.v. cannula placements were verified prior to behavioral testing by 
assessing the hyperglycemic response to 5-thio-D-glucose (210 µg) as described 
(Hayes et al., 2009). mNTS injection sites were confirmed anatomically following a 
postmortem injection of 100 nl pontamine sky blue. Only animals passing functional or 
histological verifications were included in the final statistical analysis. 
Immunohistochemical analyses 
Detection and cellular localization of fluorescently-labeled Ex-4.  
Rats were injected with fluorophore-labeled Ex-4 (fluoro-Ex-4; AnaSpec) 
intraperitoneally (10 µg/ml/kg; given ad libitum access to chow, vegetable shortening, 
and 30% sucrose). This ligand has been shown to bind to GLP-1R in cultured GLP-1R-
expressing pancreatic beta cells (Rajan et al., 2015). Three hours after injection, rats 
were transcardially perfused with 4% paraformaldehyde in PBS followed by 
cryoprotection in 20% sucrose. This time point was selected based on previous research 
showing that the anorectic effects of central Ex-4 do not develop until 3 h post-
administration (Hayes et al., 2011b; Kanoski et al., 2011; Kanoski et al., 2012a). Brains 
were sectioned on a cryostat in the coronal plane at 30 µm. Hindbrain sections were 
collected at the level of the area postrema (from bregma, AP -13.6 mm to -14.2 mm). 
Briefly, sections were blocked in 0.1 M PBS containing 5% normal donkey serum and 
0.2% Triton-X at room temperature. Sections were incubated in primary antibodies 
overnight, and then following a PBS rinse, they were incubated in secondary antibodies 
for 2 h. Primary antibodies used were rabbit anti-NeuN (ab177487, 1:1000, Abcam) and 
goat anti-GFAP (ab53554, 1:1000, Abcam). Secondary antibodies (Jackson 
Immunoresearch) were donkey anti-goat Alexa Fluor 594 (1:500) and donkey anti-rabbit 
AMCA (1:200; Figure 2) or donkey anti-rabbit Alexa Fluor 647 (1:500; Figure 3). 
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Sections were visualized with a Leica SP5 X confocal microscope using the 20x and 63x 
oil immersion objectives and the 405, 488, and 594 laser lines. Image z-stacks with the 
63x oil immersion were collected with a step size of 1 µm, while 2-3x optical zoom z-
stack images using the same objective were collected with a step size of 0.5 µm. All 
images were collected sequentially to avoid contamination of signals from other 
fluorophores. Three-dimensional rotational animations were rendered from the collected 
z-stack images using Imaris 8.1.2 (Bitplane). To generate these animations, a Gaussian 
blur was first applied to the green channel (fluoro-Ex-4) to smooth the background using 
default settings (filter size 0.174 µm). For the blue channel (NeuN), a median filter (3 x 3 
x 1 pixels) was run. Finally, the thresholds and gamma settings were adjusted [Green: 
thresholds = 4-40, gamma 2.5; Blue: thresholds = 2-90, gamma 3; Red (GFAP): 
thresholds = 2-200, gamma 1.2].  
To evaluate whether the uptake of fluoro-Ex-4 into cells is GLP-1R-mediated, 
separate rats were given a 4th i.c.v. pretreatment with either the competitive GLP-1R 
antagonist exendin-(9-39) (Ex-9, 100 µg, American Peptide) or vehicle [2 µl artificial 
cerebrospinal fluid (aCSF; Harvard Apparatus)] 20 min before ip injection of fluoro-Ex-4 
(10 µg/ml/kg). Rats were transcardially perfused 3 h later (4% paraformaldehyde in PBS 
followed by cryoprotection in 20% sucrose), and brains were immunohistochemically 
processed for NeuN, GFAP, and the fluorescently-tagged Ex-4 as described above. 
Three-dimensional rotational animations were generated for Ex-9-treated sections as 
described above. To evaluate colocalization of fluoro-Ex-4 in neurons and astrocytes 
from animals in each treatment group, z-stacks were obtained from 63x with a 2-3x 
optical zoom (vehicle: 5 z-stacks from 3 animals; Ex-9: 10 z-stacks from 3 animals) and 
colocalization analysis was performed in Imaris (version 7.6.5). The Gaussian filter was 
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applied to the green (Fluoro-Ex-4) channel using default settings (0.175 µm), the median 
filter was applied to the red (GFAP) and blue (NeuN) channels (3 x 3 x 1 px), and an 
additional Gaussian filter was applied to the blue (NeuN) channel (0.175 µm). The Imaris 
Colocalization module was then run using manual threshold settings (Green 4, Red 5, 
Blue 2) to generate a colocalization channel and statistics were exported. For each 
treatment (vehicle or Ex-9), separate Pearson's correlation coefficients (PCCs) were 
generated for colocalization of green and red (Fluoro-Ex-4 in astrocytes) and green and 
blue (Fluoro-Ex-4 in neurons).  
Triple-labeling of GLP-1/GFAP/synaptophysin. Rats were perfused transcardially 
with ice-cooled 0.9% saline, followed by 4% paraformaldehyde in 0.1 M borate buffer of 
pH 9.5. The brains were removed and immersed in fresh fixative containing 12% 
sucrose for 20–24 h at 4ºC. The brains were then blocked transversely at the level of the 
caudal midbrain, and each block was flash-frozen in dry-ice cooled hexane before being 
sectioned frozen on a sliding microtome (transverse plane, 30 µm thickness, 5 series). 
Hindbrain sections were collected at the level of the area postrema (from bregma, AP -
13.6 mm to -14.2 mm). Sections were stored in antifreeze solution at -20°C until further 
processing.  
For simultaneous immunohistochemical detection of GLP-1, GFAP, and 
synaptophysin, all washes and incubations were completed at room temperature unless 
otherwise noted. All primary and secondary antibodies were diluted in a solution of 
KPBS containing 2% donkey serum and 0.02% sodium azide. Three primary antibodies 
(rabbit anti-GLP-1, goat anti-GFAP, and mouse anti-synaptophysin) were used for this 
study. For each primary antibody used, a standard control was performed in which the 
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primary antibody was omitted from the protocol (to control for non-specific signal 
resulting from subsequent antibody and signal-detection reagents). 
Tissue was washed with 0.02 M potassium phosphate-buffered saline (KPBS) to 
remove antifreeze, and then sections were permeabilized with 0.3% Triton X-100 in 
KPBS for 30 min. After KPBS washes, the tissue went through a blocking step of 30 min 
in 2% normal donkey serum at room temperature. Tissue was incubated overnight (~18 
h) at 2ºC in rabbit anti-GLP-1 antibody (T-4363, 1:5000, Peninsula Labs). After KPBS 
washes, tissue was incubated for 48 h with goat anti-GFAP (ab53554, 1:500, Abcam) 
and mouse anti-synaptophysin (61012, 1:1000, PROGEN Biotechnik). Next, sections 
were washed and then incubated overnight at 2ºC in donkey anti-rabbit secondary-Cy3 
conjugate (1:500, Jackson Immunoresearch), donkey anti-goat secondary-AMCA 
conjugate (1:500, Jackson Immunoresearch), and donkey anti-mouse secondary-AF488 
conjugate (1:500, Jackson Immunoresearch). Sections were mounted onto glass slides 
and coverslipped using 50% glycerol in KPBS mountant. Photomicrographs were 
acquired as optical slices using a Zeiss LSM 700 UGRB confocal system controlled by 
Zeiss Zen software. 
Live cell calcium imaging 
 To prepare brainstem sections for live cell calcium imaging experiments, the 
dyes Calcium Green-1 AM (CG; Life Technologies) and sulforhodamine 101 (SR101; 
Molecular Probes) were injected into the NTS of rats (n=6) as previously described 
(Hermann et al., 2009; Vance et al., 2015). CAG is a calcium reporter dye that labels 
both neurons and astrocytes, while SR101 labels only astrocytes (McDougal et al., 
2011), allowing us to discriminate between astrocytes and neurons in our imaging 
recordings. Cellular uptake of these dyes occurred within 30-45 min. The anesthetized 
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rats were decapitated, and the brainstem was quickly harvested. Pre-labeled brainstem 
was cut into coronal sections (300 µm) on a vibrating microtome (Leica VT1200) and 
submerged in a cold (4oC) carbogenated (95% O2 / 5% CO2) cutting solution [detailed 
descriptions in (Vance et al., 2015)].  
 Live cell calcium imaging of prelabeled astrocytes and neurons was performed 
as previously described (Hermann et al., 2009; Vance et al., 2015). Hindbrain slices 
were placed in and acclimated to the recording chamber of a Nikon F1 fixed stage 
upright microscope with constant exposure to Krebs’ recording solution. Each slice was 
exposed to only one of two experimental designs. In one experiment, the slice was 
exposed to 100 nM Ex-4 in the perfusion media for 80 s and responses were monitored 
for a minimum of 3 min. In the other experiment, the slice was pre-treated with the 
competitive GLP-1R antagonist Ex-9 [200 nM; (Schepp et al., 1994)] for 5 min and then 
exposed to Ex-4 for 3 min. For both designs, slices were then washed out with normal 
Krebs’ for 10 min and next were stimulated by exposure to Krebs’ recording solution 
containing 100 µM ATP and 500 µM L-glutamate for 80 s. This ATP/glutamate challenge 
was used as a control to confirm that the neurons and astrocytes were viable and 
capable of producing calcium signals in response to experimental agonists. Only those 
cells (astrocytes and neurons) that responded to the ATP/glutamate challenge were 
included in the response analysis. Our previous studies (Vance et al., 2015) have shown 
that response magnitudes of neurons or astrocytes to ATP/glutamate do not decline 
even after multiple exposures.  
A Prairie Technologies (Bruker Corporation) line-scanning laser confocal head 
equipped with a Photometrics CoolSNAP HQ camera performed time-lapse laser 
 
30 
	
confocal calcium imaging. Nikon Elements AR software was used to analyze the 
confocal live cell fluorescent signals in the astrocytes and neurons as previously 
described (Hermann et al., 2009; Vance et al., 2015). Individual astrocytes and neurons 
were designated as regions of interest (ROI), and their fluorescence signal over time 
was captured.  Background fluorescence was subtracted from the fluorescence signal. 
The relative changes in cytoplasmic calcium in the cells were expressed as changes in 
fluorescence [(ΔF/F)%], where F is the intensity of the baseline fluorescence signal 
before stimulation, and ΔF is the difference between the peak fluorescence intensity and 
the baseline signal. Minimum of 5% change in fluorescence per cell was required to be 
included in analysis (McDougal et al., 2011).  
Intracellular cAMP signaling response of immortalized medullary rat astrocytes  
 Immortalized rat type-1 astrocyte DI-TNC1 cells (ATCC) were maintained at 37°C 
in 5% CO2 and were cultured in 1x DMEM with with 4.5 mg/ml glucose 
(GIBCO/Invitrogen), 10% (v/v) fetal bovine serum (Thermo Fisher Scientific Inc.), and 
2% penicillin (10,000 I.U./ml)-streptomycin (10,000 ug/ml) solution (Mediatech, Inc.). 
Separate plates of DI-TNC1 cells were treated with one of three GLP-1R agonists [GLP-
1 (American Peptide), Ex-4 (American Peptide), or liraglutide (Bachem)]. Three hour 
serum-starved DI-TNC1 astrocytes, cultured in a 96-well culture plate (6 × 104 
cells/well), were treated with three doses of each agonist (0.1, 0.5, or 1.0 nmol; 3 plates 
per agonist/dose combination) for 15 min. cAMP levels were calculated using a standard 
curve of fmol of cAMP/104 DI-TNC1 cells. The same vehicle treatment (n=9 plates) was 
used for comparison to each GLP-1R agonist. 
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Feeding behavior 
Comparison of 4th i.c.v. Ex-4 versus fluorophore-labeled Ex-4. Approximately 15 
min before dark cycle onset, ad libitum-fed rats (n=4) received an i.c.v. injection of Ex-4 
(0.3 µg), fluorophore-labeled Ex-4 (0.3 µg), or vehicle (1 µl aCSF). Doses of Ex-4 were 
chosen based on the literature (Hayes et al., 2011b), and each rat received all 
treatments in a counterbalanced within-subjects design. At dark onset, rats were 
presented with pre-weighed chow and intakes were recorded to the nearest 0.1 g at 1, 3, 
6, and 24 h post food presentation. Body weights were recorded at 0 and 24 h after 
injection. Injections were separated by a minimum of 72 h. 
mNTS inhibition of astrocyte activity. Approximately 30 min before dark cycle 
onset, ad libitum-fed rats (n=5) received a unilateral intra-mNTS pretreatment of vehicle 
(100 nl 0.1 M PBS) or the astrocyte Krebs cycle inhibitor fluorocitrate (DL-fluorocitric acid 
barium salt, Sigma-Aldrich; 413 ng) followed by a second unilateral mNTS injection of 
aCSF (100 nl) or Ex-4 (0.05 µg) in a within-subject counterbalanced design. At dark 
onset, rats were presented with pre-weighed chow and intakes were recorded to the 
nearest 0.1 g at 1, 3, 6, and 24 h post food presentation. Body weights were recorded at 
0 and 24 h after injection and injections were separated by a minimum of 72 h. 
Statistical analyses 
Data for all experiments are expressed as mean ± SEM, with significance set at 
p<0.05. To assess colocalization of fluoro-Ex-4 in NTS cells, PCCs for the different 4th 
i.c.v. drug conditions (vehicle or Ex-9) were compared by separate two-tailed t-tests for 
each cell type (neurons or astrocytes). The PCC for astrocyte colocalization in one z-
stack from an Ex-9-treated animal was a statistical outlier (greater than 2 standard 
deviations from the mean) and that z-stack was eliminated from all statistical analyses. 
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In vitro cAMP data were analyzed by separate one-way ANOVAs, followed by Dunnett’s 
post hoc analysis when the overall ANOVA was significant. For calcium imaging studies, 
data were evaluated using the Mann-Whitney U-test. Results of the feeding studies were 
analyzed by one-way or two-way mixed design ANOVA, with drug condition as a within-
subjects factor, and comparisons between treatment groups were made by Dunnett’s 
(4th i.c.v.) or Student Neuman-Keuls (mNTS) post hoc tests. Analyses were performed 
using Statistica 12.0 or 13.0 (StatSoft). 
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Results 
Astrocytes and neurons in the NTS express GLP-1Rs and internalize GLP-1R ligands 
To provide anatomical evidence that GLP-1Rs are expressed on astrocytes in 
the NTS, we tested the uptake of a fluorophore-labeled version of the GLP-1R agonist 
exendin-4 (fluoro-Ex-4) by neurons and astrocytes in the NTS, given the lack of a 
validated commercially-available GLP-1R-selective antibody. First, we verified that 
fluoro-Ex-4 has a comparable pharmacokinetic profile of effect on food intake and body 
weight as an equal dose of unlabeled Ex-4 when administered 4th i.c.v. in rats (Figure 1; 
feeding, F2,6=6.92, p=0.03; body weight gain, F2,6=6.36, p=0.03; for both feeding and 
body weight gain, vehicle versus Ex-4 or fluoro-Ex-4, p<0.05, Ex-4 versus fluoro-Ex-4, 
p>0.05). Fluoro-Ex-4 was then injected systemically (10 µg/kg, i.p.) and the animals 
were transcardially perfused 3 h later. The brains were immunohistochemically 
processed to label astrocytes and neurons, in conjunction with visualization of fluoro-Ex-
4. Confocal microscopy revealed co-localization of fluoro-Ex-4 in both GFAP-positive 
astrocytes and NeuN-positive neurons in the NTS following systemic delivery (Figure 2). 
Further, a 3-dimensional rotation video of 63x z-stack overlays within the NTS revealed 
that systemically delivered fluoro-Ex-4 was internalized by both NTS astrocytes and 
neurons (See Figure 2C for still from video). This movie avoids the possibility of false 
overlaps that may exist in the 2-dimensional image (e.g., fluoro-Ex-4 directly in front of or 
behind the cell may appear to be co-localized in a 2-dimensional image, but not in a 3-
dimensional rotation). 
To confirm that the binding and uptake of fluoro-Ex-4 in NTS cells is GLP-1R-
mediated, we tested whether internalization of peripherally-administered fluoro-Ex-4 
would be attenuated by pharmacological blockade of hindbrain GLP-1Rs. As shown in 
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the Figure 3A and similar to our first study, fluoro-Ex-4 was co-localized in both 
astrocytes and neurons in the NTS after 4th i.c.v. pretreatment with vehicle (2 µl). 
However, hindbrain injection of the competitive GLP-1R antagonist exendin-(9-39) (Ex-9; 
100 µg) blocked uptake of fluoro-Ex-4 in NTS cells (Figure 3B and C). Quantitative 
analyses suggest that Ex-9 pretreatment blocks colocalization of fluoro-Ex-4 in both 
astrocytes [vehicle: r = 0.20±0.12; Ex-9: r = -0.07±0.03; t(12)=2.75, p=0.02] and neurons 
[vehicle: r = 0.23±0.10; Ex-9: r = 0.03±0.04; t(12)=2.36, p=0.04]. Although this analysis 
does not account for the location of the fluoro-Ex-4 (e.g., on the cell surface versus 
internalized), as Ex-9 is a competitive GLP-1R antagonist, it would likely block both 
receptor binding and internalization of the agonist. Collectively, these data provide 
further evidence that uptake of the fluorescently-tagged Ex-4, like untagged Ex-4, is 
mediated by the GLP-1R. Again, inclusion of a 3D rotational video (see Figure 3C for 
still) avoids the potential for false overlaps in the 2-dimensional image in Figure 3B. 
These data provide novel anatomical evidence suggesting that astrocytes bind 
and take up GLP-1R ligands; these results also show that a peripherally-injected GLP-
1R agonist can penetrate the blood-brain barrier and gain access to the NTS. 
Furthermore, these data show that a portion of astrocytes and neurons do not take up 
the fluoro-Ex-4, suggesting that these cells do not express the GLP-1R, while other cells 
in adjacent proximity show clear uptake of the fluoro-Ex-4 and putatively express GLP-
1Rs (shown explicitly in Figure 2). 
NTS astrocytes and neurons show increased live cell calcium signaling following Ex-4-
induced GLP-1R activation  
To test the ability of astrocytes in the NTS to respond to GLP-1R activation, ex 
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vivo live cell calcium signaling in NTS-containing rat brainstem slices was evaluated 
following bath application of Ex-4 (100 nM). Astrocytes were pre-labeled with the 
astrocyte-specific dye SR101, and both astrocytes and neurons were pre-labeled with 
the calcium-sensitive dye CalciumGreen-1 AM (CG; Figure 4A-C). An increase in 
intracellular calcium corresponded to an increase in fluorescence and is indicative of 
cellular activation (Rogers et al., 2006). In viability experiments, ATP/glutamate 
stimulation activated 129 NTS astrocytes with a mean magnitude of increased 
fluorescence of 24.6 + 1.2% (Figures 4D, F, G). Of the 129 NTS astrocytes responsive 
to the ATP/glutamate challenge, 40% were also directly responsive to Ex-4 stimulation 
(Figure 4E, F) with a 20.1 + 4.2% mean magnitude of response (Figure 4G), similar in 
magnitude to the response to ATP/glutamate. A similar proportion of NTS neurons were 
responsive to Ex-4 stimulation (14 out of 38 ATP/glutamate-responsive neurons; Figure 
4E, F). Those neurons that were responsive to both stimuli averaged lower magnitudes 
in their response to Ex-4 relative to their evoked response to ATP/glutamate (Figure 4H). 
In separate hindbrain slices, pre-exposure to the competitive GLP-1R antagonist 
Ex-9 reduced the overall number of Ex-4-responsive astrocytes from 40% to 
approximately 20% (Figure 4F). NTS astrocytes that were still activated by Ex-4 
following Ex-9 pre-exposure had a significantly diminished response to Ex-4 (Figure 4G; 
U=37, p=0.0002). In contrast, while Ex-9 suppressed the number of NTS neurons 
responsive to Ex-4 from ~37% to 13% (Figure 4F), the magnitude of their response to 
Ex-4 was not further inhibited by Ex-9 (Figure 4H; U=20, p=0.53).  
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GLP-1R activation increases cAMP in astrocytes in vitro 
Downstream intracellular signaling events of GLP-1R activation in neurons 
include elevated levels of cAMP and PKA, which are required for the anorexigenic 
effects of GLP-1R activation (Hayes et al., 2011b). However, it is unknown whether this 
signaling pathway is also recruited by astrocytic GLP-1R activation. To determine 
whether GLP-1R activation increases cAMP levels specifically in astrocytes, we 
measured cAMP concentration in an immortalized rat type-1 astrocyte cell line (DI-
TNC1) after exposure to one of three GLP-1R agonists [GLP-1(7-36), exendin-4 (Ex-4), 
or liraglutide; 0.1, 0.5, 1.0 nmol]. These in vitro analyses demonstrated that each of the 
three GLP-1R ligands caused a significant dose-dependent increase in cAMP 
concentrations in astrocytes (Figure 5; GLP-1: F3,14=3.74, p=0.04; Ex-4: F3,14=6.02, 
p=0.01; liraglutide: F3,14=6.12, p=0.01). These data suggest that like the cAMP 
responses previously observed in neurons (Hayes et al., 2011b), cAMP signaling is 
engaged downstream of GLP-1R activation in astrocytes.  
Endogenous GLP-1-immunopositive fibers form synaptic contact with NTS astrocytes 
To provide evidence of a potential endogenous source of GLP-1 to NTS 
astrocytes, immunohistochemical triple-labeling was performed to identify GLP-1 axons, 
astrocytes (GFAP-immunopositive), and presynaptic terminals (synaptophysin-
immunopositive) in the NTS of rats. As shown in Figure 6, GLP-1 and synaptophysin co-
localized in NTS GFAP-positive astrocytes, indicating that GLP-1 axons terminate in 
close apposition (presumably synaptic contacts) to NTS GFAP-positive astrocytes. 
These anatomical data suggest that NTS PPG neurons are a putative endogenous 
source of GLP-1 to NTS astrocytes. 
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Astrocytes mediate the food intake- and body weight-suppressive effects of GLP-1R 
activation in the NTS 
To test whether NTS astrocytes play a role in the energy balance effects of GLP-
1R activation, food intake and body weight gain was measured in rats following NTS-
targeted treatment with the astrocyte Krebs cycle inhibitor fluorocitrate (Lian and 
Stringer, 2004; Hermann et al., 2014) (413 ng) and Ex-4 (0.05 µg). As shown in Figure 7, 
NTS pre-treatment with fluorocitrate attenuated both the hypophagia and body weight 
reduction produced by direct NTS administration of Ex-4 [24 h food intake: interaction 
between fluorocitrate and Ex-4, F1,4=10.08, p=0.03; body weight: F1,4=33.87, p=0.004; 
for both 24 h food intake and body weight, vehicle/vehicle vs. vehicle/Ex-4, p<0.05; 
vehicle/Ex-4 vs. fluorocitrate/Ex-4, p<0.05; no statistically significant interaction between 
fluorocitrate and Ex-4 at 1, 3, or 6 h (all F1,4≤1.04, all p≥0.37; data not shown)]. 
Importantly, behavioral data from animals (n=5) with missed mNTS cannula placements 
does not show hypophagia after GLP-1R activation or an effect of fluorocitrate (See 
Figure A1 in Appendix; (F1,4<3.6, p>0.13). These findings suggest that inhibiting 
astrocyte activity attenuates the ability of NTS GLP-1R activation to promote negative 
energy balance. 
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Discussion 
Astrocytes play a critical role in the regulation of glutamatergic 
neurotransmission, yet are surprisingly understudied as potential mediators of energy 
balance-relevant signals. Given that the food intake- and body weight-suppressive 
effects of central GLP-1R signaling are mediated in part by presynaptic modulation of 
glutamate signaling (Hisadome et al., 2011; Mietlicki-Baase et al., 2013a; Mietlicki-
Baase et al., 2014), it is intriguing to consider the idea that GLP-1Rs expressed on 
astrocytes may influence glutamate signaling to affect energy balance. Therefore, we 
focused our attention on astrocytes in the NTS because of the critical role this nucleus 
serves in processing vagally-mediated glutamatergic satiation signals (Grill and Hayes, 
2012), as well as the endogenous relevance of NTS GLP-1R signaling for the normal 
control of food intake (Hayes et al., 2009). Novel data presented here show that: [1] 
astrocytes are activated by GLP-1 and GLP-1R agonists, [2] the GLP-1R agonist Ex-4 is 
internalized by and produces robust calcium signaling in NTS neurons and astrocytes, 
[3] the endogenous central GLP-1 neurons form close synaptic appositions with NTS 
astrocytes, and [4] NTS astrocyte activity is required for the hypophagia and reduction in 
body weight produced by NTS GLP-1R activation.  
Unlike the short half-life of endogenous peripheral GLP-1, systemically 
administered GLP-1R agonists Ex-4 and liraglutide are resistant to degradation by DPP-
IV and thus remain in circulation for longer periods of time to impact energy balance 
(Kanoski et al., 2011; Secher et al., 2014; Sisley et al., 2014). These drugs are used 
clinically for the treatment of T2DM, and more recently, liraglutide also has been FDA-
approved for use in the treatment of obesity (Tella and Rendell, 2015), highlighting the 
importance of fully understanding the mechanisms by which these GLP-1R agonists 
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exert their metabolic effects. To address the ability of GLP-1R agonists to activate NTS 
astrocytes, an important first step was to confirm GLP-1R expression on astrocytes. 
Given the lack of a validated commercially-available GLP-1R-selective antibody, we 
instead availed of a novel use of fluorophore-tagged Ex-4 and tested its ability to label 
GLP-1R expressing neurons and astrocytes in the NTS. Injection of fluoro-Ex-4 
peripherally revealed that some, but not all NTS astrocytes and neurons were labeled 
with the fluorescent tag, indicating binding of the ligand and thus probable GLP-1R 
expression. The finding that uptake of peripherally-administered fluoro-Ex-4 was blocked 
by hindbrain pretreatment with Ex-9 provides further support for GLP-1R mediation of 
these effects. These results also provide visual evidence that this long-lasting GLP-1R 
agonist can cross the blood-brain barrier and bind to receptors within the CNS. Perhaps 
most intriguing is the discovery that fluoro-Ex-4 was internalized by not only neurons but 
also astrocytes.  
A combination of in vitro and ex vivo approaches was used to demonstrate that 
astrocytes not only internalize a GLP-1R agonist, but also are responsive to GLP-1R 
activation. Ex vivo live cell calcium imaging data indicated that subpopulations of 
astrocytes as well as neurons within the NTS are responsive to GLP-1R activation. 
Approximately 40% of all viable NTS astrocytes and neurons also responded to Ex-4. 
However, pre-exposure of the slice to the competitive GLP-1R antagonist Ex-9 reduced 
the numbers of NTS astrocytes and neurons responding to Ex-4. Furthermore, the 
magnitude of the NTS astrocyte response to Ex-4 was also reduced by Ex-9; in contrast, 
Ex-9 pretreatment did not further blunt the magnitude of response to Ex-4 in neurons 
that remained responsive. This observation opens the possibility that NTS neuron 
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responses to Ex-4 may actually be activated, at least in part, by an indirect 
gliotransmission driven pathway following GLP-1R activation of astrocytes.  
To directly examine whether GLP-1R-mediated calcium signaling engages cAMP 
as a second messenger in astrocytes, an immortalized rat type-1 astrocyte DI-TNC1 cell 
line was utilized. Similar to the response previously observed in neuronal cultures 
(Hayes et al., 2011b), cAMP levels increased dose-dependently in the rat astrocyte cell 
line following activation by any one of three GLP-1R agonists tested (GLP-1, Ex-4, or 
liraglutide). Together, these data suggest that GLP-1R activation and recruitment of the 
appropriate intracellular signaling cascades occur not only in neurons but also in 
astrocytes.  
Previous research has shown that endogenous NTS GLP-1R signaling is 
physiologically relevant for food intake control, as blockade of endogenous NTS GLP-1R 
by hindbrain administration of the GLP-1R antagonist exendin-(9-39) leads to a 
significant increase in food intake (Hayes et al., 2009). However, it is unknown whether 
this effect is due to blockade of GLP-1R expressed on NTS neurons, astrocytes, and/or 
vagal afferent terminals. Given that PPG neurons within the NTS synthesize GLP-1, 
endogenous GLP-1 produced within the NTS could engage astrocytes for energy 
balance control. Indeed, the novel immunohistochemical analyses presented here 
provide anatomical evidence that endogenous GLP-1 axons make close appositions with 
NTS astrocytes. This finding does not establish whether these points of contact are 
classical “synapses”, and it remains unclear whether true synaptic communication 
occurs at these apposed membranes or whether the GLP-1 axons and NTS astrocytes 
interact in some other way. Nevertheless, these close appositions are suggestive of an 
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interaction between the GLP-1-producing neurons and astrocytes, and future studies are 
therefore warranted to examine the contribution of endogenous, astrocyte-specific GLP-
1R signaling for the control of energy balance.  
Behavioral food intake and body weight analyses demonstrated that inhibition of 
NTS astrocyte metabolic function with fluorocitrate attenuated the intake- and body 
weight suppression produced by NTS GLP-1R activation. This finding provides support 
for the hypothesis that NTS astrocytes not only bind, internalize, and display appropriate 
signaling responses to GLP-1R agonists, but also that NTS astrocytes mediate the 
energy balance effects of GLP-1R signaling. Fluorocitrate inhibits glial cells by blocking 
aconitase activity, thereby disrupting the tricarboxylic acid (TCA) cycle (Peters, 1957; 
Brand et al., 1973; Fonnum, 1997). Although multiple types of glia can be inhibited by 
fluorocitrate, it appears to have the most potent effects on astrocytes (Paulsen et al., 
1987). Any potential influence of oligodendrocytes or microglia on the behavioral effects 
observed in this experiment would likely be minimal in comparison to the contributions of 
astrocytes, but this possibility cannot be ruled out. It should also be noted that at very 
high doses, fluorocitrate can also disrupt neuronal activity (Koenig, 1969), but the dose 
used in our study (413 ng, or 0.5 nmol) is far below subthreshold concentrations for 
neuronal effects (Paulsen et al., 1987; Hassel et al., 1992; Willoughby et al., 2003).  
As fluorocitrate blocks all astrocyte activity, it is impossible to tease apart the 
exact role of astrocytes in mediating GLP-1R intake suppression by this pharmacological 
manipulation. For example, we cannot definitively exclude the possibility that astrocytes 
are indirectly involved with the behavioral effects of GLP-1R activation. That is, NTS 
injection of fluorocitrate will non-selectively inhibit all NTS astrocytes, not only GLP-1R-
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expressing astrocytes, so one cannot rule out the alternative explanation that astrocytes 
are also engaged along with or even downstream of neuronal GLP-1R activation, or that 
non-GLP-1R-expressing astrocytes may play some indirect role in these anorexic 
effects. However, the results of the calcium imaging studies argue against these 
possibilities. The near-simultaneous activation of NTS astrocytes and neurons by Ex-4 in 
that experiment supports the hypothesis that Ex-4 acts directly on at least a subset of 
NTS astrocytes. Even if GLP-1R activation in these astrocytes accompanies neuronal 
GLP-1R activation, our behavioral data suggest that astrocytes are required for the 
control of energy balance by NTS GLP-1R activation.  
An important empirical question arising from the current studies is the 
mechanism by which astrocytic GLP-1R activation might alter glutamatergic 
neurotransmission to subsequently affect energy balance. Increased cAMP levels have 
been linked to reduced expression of glutamate transporters (Lim et al., 2005). Our data 
demonstrating that astrocytic GLP-1R activation elevates cAMP hints at the intriguing 
possibility that astrocytic glutamate transporters (e.g. GLT-1, GLAST) may be 
downregulated as a result of GLP-1R activation, providing a potential mechanism by 
which GLP-1R signaling in astrocytes could increase glutamate in the NTS synapse and 
consequently reduce food intake (Ritter, 2004; Hisadome et al., 2011; Mietlicki-Baase et 
al., 2013a; Mietlicki-Baase et al., 2014). 
 Collectively, the current data show that NTS astrocytes are engaged by GLP-1R 
activation to control energy balance. Central activation of GLP-1R in a variety of nuclei 
has a broad range of behavioral and physiological effects. In addition to the NTS, 
several nuclei within the brain mediate the hypophagic effects of GLP-1 [see (Hayes et 
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al., 2014a) for review]. Additionally, CNS GLP-1R mediate diverse phenomena including 
glycemic control (Sandoval et al., 2008), motivated behavior (Harasta et al., 2015), and 
even presumably protection against neurodegeneration (Bao et al., 2015). The 
possibility that astrocytic GLP-1R activation contributes to these effects is just beginning 
to be considered. As FDA-approved drugs such as exendin-4 and liraglutide target the 
central GLP-1 system, the present findings may also be of clinical significance as the 
scientific community strives to comprehend more fully the mechanisms by which GLP-
1R agonists exert their physiological and behavioral effects. In summary, the current 
findings not only demonstrate the importance of NTS astrocytic GLP-1R signaling for the 
control of food intake, but also represent the beginning of an enormous opportunity for 
deeper understanding of the mechanisms by which central GLP-1 signaling influences 
physiology and behavior. 
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Figure 1. Hindbrain administration of fluorescently-labeled Ex-4 produces energy 
balance effects comparable to those of unlabeled Ex-4. Fourth i.c.v. administration of 
Ex-4 (0.3 µg) reduces chow intake (A) and body weight (BW) gain (B) in rats (n=4); an 
equal dose of fluorescently-labeled Ex-4 (Fluoro-Ex-4) given 4th i.c.v. causes similar 
suppression of feeding and body weight gain. The key for (a) applies to both panels. *, 
p<0.05 compared to vehicle. Data shown as mean ± SEM. 
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Figure 2. Fluorescently-labeled Ex-4 is taken up by neurons and astrocytes within 
the NTS following systemic administration. Rats (n=2) were injected with fluoro-Ex-4 
peripherally (10 µg/kg, ip) and sacrificed 3 h later. A representative NTS-containing 
section is shown at 20x magnification in (a), with GFAP-positive cells shown in red and 
NeuN-positive cells in blue. The dotted box outlined in panel (A) is magnified in (B). This 
higher-magnification image in (B) depicts a single image within a z-stack (0.5 µm step 
size) taken with the 63x oil immersion objective shows fluoro-Ex-4 labeling in GFAP-
positive cells (red) and NeuN-positive cells (blue). White arrows indicate cells lacking co-
localization with fluoro-Ex-4, while yellow arrows indicate cells that take up fluoro-Ex-4. 
The dotted box in (B) indicates the field of view in (C), which shows a still from a 
representative three-dimensional rotational video of fluoro-Ex-4 co-localization in NTS 
astrocytes and neurons following systemic administration of fluoro-Ex-4. cc = central 
canal.  
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Figure 3. The internalization of peripherally administered fluoro-Ex-4 in NTS cells 
is blocked by 4th i.c.v. pretreatment with a GLP-1R antagonist. While uptake of 
fluoro-Ex-4 (10 µg/kg, ip) was observed in NTS astrocytes and neurons of rats given a 
4th i.c.v. pretreatment with vehicle (a; n=3), central pretreatment with Ex-9 (100 µg) 
blocked this effect (b; n=4). Fluoro-Ex-4 is shown in green, GFAP-positive cells are 
shown in red, and NeuN-positive neurons are shown in blue. The smaller insets at the 
top of each panel depict representative NTS-containing coronal sections at 20x 
magnification. The boxed area of each inset was magnified to 63x and a further 2-3x 
optical zoom was applied to generate the large images. A still from the 3-dimensional 
rotational video from a subfield of B is shown in C. cc= central canal. 
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Figure 4. GLP-1R activation increases calcium signaling in subsets of both NTS 
astrocytes and neurons. NTS cells (n=6 rats) were preloaded with CalciumGreen-1 AM 
(calcium-sensitive dye; labels astrocytes and neurons) and SR101 (astrocyte-specific 
red dye); yellow colocalization confirms that the calcium-sensitive dye is localized in 
astrocytes (A-C). Astrocytes and neurons are designated as “regions of interest” (ROI); 
red = neuron, blue = astrocyte. Calcium-induced changes in fluorescence in response to 
perfusion parameters are quantitated over time. Percent change in fluorescence for each 
ROI over time is shown in corresponding line colors (neuron in red, astrocyte in blue). 
Control (viability) experiments were performed [representative traces in (D)], in which a 
cocktail of ATP/glutamate was applied for 80 sec to identify viable, responsive astrocytes 
and neurons (i.e., increased intracellular calcium as demonstrated by increased 
fluorescence). The increase in intracellular calcium is immediate due to the combined 
opening of ligand-gated cation channels and the intracellular release of stored calcium. 
Approximately 40% of NTS-astrocytes and neurons were also activated by GLP-1R 
agonist Ex-4 [representative traces in (E), quantification of cells in (f)]. Pre-exposure of 
the slice to the competitive GLP-1R antagonist Ex-9 reduces the number of Ex-4 
responsive cells to approximately 20% (F). The subpopulation of NTS astrocytes 
activated by Ex-4 exhibits a similar magnitude of calcium response as that elicited by the 
ATP/glutamate cocktail, but pre-exposure to Ex-9 reduces the magnitude of this 
response (G). In contrast, the magnitude of the calcium response in neurons to Ex-4 was 
not further inhibited by Ex-9 (H). For (G) and (H), data shown as mean ± SEM. *, p<0.05. 
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Figure 5. GLP-1R activation increases cAMP concentration in astrocytes in vitro. 
Bath application of the GLP-1R agonists GLP-1 (A), Ex-4 (B), or liraglutide (C) elevated 
cAMP levels in immortalized rat type-1 astrocytes (DI-TNC1). For each agonist/dose 
combination, n=3 plates of cells; for control, n=9 plates. Data shown as mean ± SEM. *, 
p<0.05; #, p<0.08 compared to control (dose 0). 
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 Figure 6. GLP-1-containing axons form close appositions with NTS astrocytes. 
Representative 1.5 µm thick images from NTS-containing transverse sections (n=3 rats) 
show GLP-1 in magenta, GFAP (astrocyte marker) in blue, and synaptophysin in green. 
White arrows indicate triple-labeling, providing evidence for synaptic-like contacts 
between GLP-1-containing cells and astrocytes in the NTS. The top orthogonal in (A) 
represents the XZ plane for the Z stack, whereas the right orthogonal represents the YZ 
plane for the Z stack. The cross hairs in this panel (red vertical line meets green 
horizontal line) highlight one of several examples of three-label evidence for appositions 
at this level of the NTS. The inset in (B) reveals this at higher resolution, with the three-
label example at the cross hairs in (A) represented by the top arrow in (B). AP = area 
postrema. 
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Figure 7. Inhibition of mNTS astrocytes attenuates the food intake- and body 
weight-suppressive effects of mNTS GLP-1R activation. Rats (n=5) were given an 
intra-mNTS pretreatment with the astrocyte Krebs cycle inhibitor fluorocitrate or its 
vehicle, followed by direct mNTS administration of the GLP-1R agonist Ex-4. 
Fluorocitrate, at a dose that on its own had no effect on chow intake or body weight gain, 
significantly attenuated the ability of intra-mNTS Ex-4 to reduce chow intake (A) and 
body weight gain (B) over the 24h post-injection. * significantly different from 
vehicle/vehicle (p<0.05); Ŧ p<0.05 versus vehicle/Ex-4. Key applies to both panels. Data 
shown as mean ± SEM. 
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Abstract 
 Glucagon-like peptide-1 (GLP-1) synthesized in the nucleus tractus solitarius 
(NTS) of the hindbrain is physiologically required for the normal control of food intake, 
while pharmacological GLP-1 receptor (GLP-1R) agonists are FDA-approved for the 
treatment of diabetes and obesity. However, the neurobiological substrates that mediate 
the anorectic effects of both endogenous GLP-1 and exogenous GLP-1R agonists 
require further investigation. As the lateral dorsal tegmental nucleus (LDTg) expresses 
the GLP-1R and represents a potential neuroanatomical hub connecting the NTS with 
the other nuclei in the midbrain and forebrain, we tested the hypothesis that GLP-1R 
signaling in the LDTg regulates food intake. Direct activation of LDTg GLP-1R 
suppresses food intake through a reduction in meal size and independent of 
nausea/malaise. Immunohistochemical data show that GLP-1-producing neurons in the 
NTS project to the LDTg, providing anatomical evidence of endogenous central GLP-1 in 
the LDTg.  Pharmacological blockade of LDTg GLP-1Rs with exendin-(9-39) dose-
dependently increases food intake and attenuates the hypophagic effects of gastric 
distension. As GLP-1 mimetics are administered systemically in humans, we evaluated 
whether peripherally administered GLP-1R agonists access the LDTg to affect feeding. 
Immunohistochemical data show that a systemically-administered fluorescent GLP-1R 
agonist accesses the LDTg and is juxtaposed with neurons. Additionally, blockade of 
LDTg GLP-1Rs attenuates the hypophagic effects of a systemic GLP-1R agonist. 
Together, these data indicate that LDTg GLP-1R signaling controls energy balance and 
underscores the role of the LDTg in integrating energy balance-relevant signals to 
modulate feeding.  
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Introduction 
 Among the many hormones, neuropeptides, and neurotransmitters that influence 
feeding behavior, the glucagon-like peptide-1 (GLP-1) system stands out as a key 
regulator of physiological and behavioral processes involved in glycemic and food intake 
control (Grill and Hayes, 2012). Within the central nervous system (CNS), GLP-1 is 
produced from the preproglucagon (PPG) neurons of the caudal nucleus tractus 
solitarius (NTS). These PPG neurons project widely throughout the CNS (Dossat et al., 
2011; Alhadeff et al., 2012; Kanoski et al., 2016), suggesting that GLP-1 receptor (GLP-
1R) populations that are distributed across the neuraxis (Merchenthaler et al., 1999) are 
activated by centrally-produced GLP-1, either through direct projections of PPG neurons 
or through volume transmission (Dossat et al., 2011; Alhadeff et al., 2012; Hsu et al., 
2015; Kanoski et al., 2016). However, the functional role of each of these GLP-1R 
populations in mediating the intake suppressive effects of exogenous GLP-1R agonists 
and/or endogenous NTS-derived GLP-1 remains largely unresolved. This gap in our 
knowledge is of clinical significance, as FDA-approved GLP-1R agonists penetrate into 
the CNS to activate central GLP-1Rs to suppress food intake (Hayes et al., 2011a; 
Kanoski et al., 2016; Reiner et al., 2016).  
 The lateral dorsal tegmental nucleus (LDTg) of the mesopontine tegmentum 
expresses GLP-1Rs (Merchenthaler et al., 1999), receives axonal projections from the 
hindbrain, hypothalamus, and midbrain structures (Cornwall et al., 1990), and is 
anatomically positioned to serve as a potential hub modulating energy balance and 
motivated behavior (Reiner et al., 2017). Indeed, prior research has shown that other 
neuropeptide systems act in the LDTg to modulate energy balance, establishing a role 
for the LDTg in food intake and meal size control, body weight regulation, and appetitive 
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behavior (Dickson et al., 2010; Dickson et al., 2011; Jerlhag et al., 2012; Reiner et al., 
2017). The NTS projects to the LDTg, and critically, these projections originate at the 
same rostral-caudal level as NTS PPG neurons (Cornwall et al., 1990). This suggests 
that a portion of these LDTg-projecting NTS neurons is GLP-1-positive and may provide 
an endogenous central source of GLP-1 to the LDTg. As the NTS receives input from 
the gastrointestinal (GI) tract via the vagus nerve (Grill and Hayes, 2009, 2012), these 
anatomical findings provide the intriguing possibility of a potential role of gut-LDTg 
signaling through a NTS-to-LDTg GLP-1 pathway.  
 Given that the LDTg expresses GLP-1R and integrates information from 
peripherally and centrally-derived energy status signals to affect energy balance 
(Dickson et al., 2010; Dickson et al., 2011; Jerlhag et al., 2012; Reiner et al., 2017), we 
examined the hypothesis that GLP-1R signaling in the LDTg is both pharmacologically 
and physiologically relevant for energy balance control. Current data show that LDTg 
GLP-1R activation decreases food intake through a reduction in meal size and 
endogenous NTS-to-LDTg GLP-1 signaling mediates the intake suppressive effects of a 
self-ingested mixed macronutrient preload. Complementary anatomical and behavioral 
data show that LDTg GLP-1Rs are a CNS site-of-action mediating the intake 
suppressive effects of systemic GLP-1R agonists. These data establish a novel role of 
GLP-1 signaling in the LDTg for energy balance control and provide further anatomical 
and behavioral evidence that the LDTg is a potential hub mediating ingestive behavior. 
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Materials and Methods 
Animals 
 Male Sprague-Dawley rats (310-325g upon arrival; Charles River, Wilmington, 
MA, USA or Harlan/Envigo, Indianapolis, IN, USA) were individually housed in hanging 
wire cages (12h light/dark cycle) and given ad libitum chow (Purina LabDiet 5001, 
Quakertown, PA, USA) and water. All procedures were approved by the Institutional 
Animal Care and Use Committee at the University of Pennsylvania and at the University 
of Southern California and were performed according to the National Institutes of Health 
guidelines. 
Drugs 
 Exendin-4 (Ex-4; Bachem, Torrance, CA, USA) was dissolved in artificial 
cerebrospinal fluid (aCSF; Harvard Apparatus, Holliston, MA, USA) for central injections 
and 0.9% sterile saline for peripheral injections. Exendin-(9-39) (Ex-9; Bachem, 
Torrance, CA, USA) was dissolved in aCSF. Fluorescent exendin-4 (FLEX; Anaspec, 
Freemont, CA, USA) was dissolved in 99.97% saline and 0.03% aCSF. 
Stereotaxic surgery 
 Animals were anesthetized with an intramuscular (IM) injection of a cocktail 
(KAX) composed of ketamine (90mg/kg), acepromazine (0.64mg/kg), and xylazine 
(2.7mg/kg) and placed in a stereotaxic apparatus. Bilateral guide cannulae (Plastics 
One, Roanoke, VA, USA) targeting the LDTg (according to Paxinos & Watson, 2004; 
coordinates: ±0.5mm lateral to midline, 8.7 mm posterior to bregma, 4.1 mm ventral to 
skull; microinjector aimed 6.6 mm ventral to skull) were implanted and affixed to the skull 
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with bone screws and dental cement. Analgesia (meloxicam, 2 mg/kg) was administered 
to all animals following surgery. Rats were allowed ~1 week recovery from surgery 
before the beginning of an experiment. LDTg injection placements were verified 
histologically postmortem by intraparenchymal injections of pontamine sky blue (100 nl). 
Animals with missed cannula placements were eliminated from analyses.  
Immunohistochemistry 
GLP-1 axon labeling in the LDTg 
 Immunohistochemical labeling of GLP-1 axons in the LDTg was performed as 
previously described (Hsu et al., 2015). Briefly, rats (n=4) were transcardially perfused 
and brains were removed and sectioned coronally at 30µm. LDTg-containing sections 
were incubated for 60h at 4°C in primary antibody for rabbit anti-GLP-1 (1:2000, 
Peninsula Labs, San Carlos, CA, USA) in potassium phosphate buffered saline (KPBS) 
with 0.1% Triton X-100. Following primary antibody incubation, sections were incubated 
overnight at 4°C with biotinylated donkey anti-rabbit (Jackson Immunoresearch, West 
Grove, PA, USA) in KPBS with 0.1% Triton X-100. Following a KPBS rinse, sections 
were incubated with KPBS with ABC reagent (1:1000, reagent A and B from ABC Elite 
kit, Vector Labs, Burlingame, CA, USA) for 4h. Following further KPBS washes, sections 
were reacted for 10 min in KPBS containing 0.005% H2O2 and 0.05% 3,3'-
Diaminobenzidine. Following final washes, the sections were mounted on glass slides, 
air-dried, and coverslipped with DePeX. Photomicrographs were taken with a digital 
camera mounted to a microscope (Nikon 80i) equipped for darkfield illumination. 
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Retrograde tracing of GLP-1 NTS-to-LDTg projections 
 Animals were anesthetized with a surgical dose of KAX and received a unilateral 
LDTg injection of 100nl of 0.25% cholera toxin B subunit (CTB; #104, List Laboratories, 
Campbell, CA, USA) over 2s, according the following coordinates (according to Paxinos 
& Watson, 2004): 0.6mm lateral to midline, 8.7 mm posterior to bregma, 4.5 mm ventral 
to skull; microinjector aimed 7.0 mm ventral to skull. After the injection, the microinjector 
was left in place for ten minutes before being removed and the incision was sutured. 
Rats were perfused seven days later. Following removal, brains were postfixed in 4% 
paraformaldehyde for 6h and cryoprotected in 20% sucrose in 0.1M PBS at 4°C for 2-3 
days. Coronal brain sections (30 µm) encompassing the NTS or LDTg were sliced and 
stored in cryoprotectant until processing. Sections were washed in 50% ethanol for 30 
min, rinsed in PBS, and then incubated in 1% sodium borohydride for 20 min. Following 
a PBS wash, sections were then blocked in PBS with 5% normal donkey serum and 
0.2%Triton-X at room temperature for 1h. NTS-containing sections were incubated 
overnight at room temperature in the following primary antibodies: mouse anti-CTB 
(1:1000, ab62429, Abcam, Cambridge, MA, USA) and rabbit anti-GLP-1 (1:1000, T-
4363, Peninsula Labs, San Carlos, CA, USA). LDTg-containing sections were incubated 
overnight in the mouse anti-CTB antibody. Following a PBS rinse, sections were 
incubated for 2h in the appropriate donkey anti-primary antibody species Alexa Fluor 
488 and 594 antibodies (Jackson Immunoresearch, West Grove, PA, USA). All antibody 
incubations were performed in blocking solution. Sections were mounted on slides and 
visualized with a Leica SP5 X confocal microscope using the 488 and 594 laser lines 
with a 20x objective. All images were collected sequentially to avoid contamination of 
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signals from other fluorophores. At least six NTS-containing sections from 14.2-14.7 mm 
posterior to bregma were used to quantify the number of CTB and PPG neurons. 
Fluorescent exendin-4 labeling in the LDTg 
 To provide anatomical evidence that a systemically administered GLP-1R agonist 
penetrates into the brain and binds to cells within the LDTg, rats received an IP injection 
of fluorescent exendin-4 (FLEX; 3 µg/kg, n=5) at the onset of the dark cycle. Rats were 
food deprived for one hour prior to dark cycle onset and food remained unavailable. 
Three hours later, rats were anesthetized with an IM injection of the surgical dose of 
KAX and transcardially perfused with 0.1M PBS followed by 4% paraformaldehyde in 
0.1M PBS. Brains were removed, postfixed, sectioned, and tissue was blocked as 
described above.  LDTg-containing sections were incubated overnight in primary 
antibodies [rabbit anti-glial fibrillary acidic protein (GFAP; 1:2000, Z0334, Dako/Agilent, 
Santa Clara, CA, USA) and mouse anti-NeuN (1:1000, MAB377, Millipore, Billerica, MA, 
USA)] in blocking solution. Following a PBS rinse, sections were incubated in 
appropriate donkey Alexa Fluor 594 and 647 secondary antibodies (Jackson 
Immunoresearch, West Grove, PA, USA) at room temperature. Sections were mounted 
on slides and visualized with a Leica SP5 X confocal microscope using the 488, 594, 
and 633 laser lines with a 63x oil immersion objective. FLEX was visualized in the LDTg 
using the 488 laser line. All images were collected sequentially to avoid contamination of 
signals from other fluorophores. Images are represented as a maximal z-stack projection 
with Fiji 2.0 or as a 3D rotational video with Imaris (8.4.1).  
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Behavioral testing 
General Procedures 
 Drug injections were performed immediately prior to the onset of the dark cycle 
unless otherwise specified. For experiments measuring ad libitum food intake, food 
weights were measured at 1, 3, 6, and 24h after injection, unless otherwise noted. Food 
weights were recorded to the nearest 0.1g, accounting for spillage. Body weight was 
measured at 0 and 24h after injection. Treatments were assigned using a within-subject 
counterbalanced design, with at least 72h between injections. 
Intra-LDTg exendin-4 dose-response experiments 
 To assess the dose-response effects of LDTg GLP-1R activation on food intake 
and body weight, rats (n=10) received unilateral LDTg injections of Ex-4 (0, 0.025, 
0.05µg; 100 nl aCSF) immediately before the onset of the dark cycle. These doses of 
Ex-4 were selected based on previous dose-response experiments in the NTS, ventral 
tegmental area (VTA), and nucleus accumbens (NAc) (Hayes et al., 2008; Alhadeff et 
al., 2012). Food intake and body weight were measured. 
 To determine if nausea/malaise contributes to the intake suppression following 
GLP-1R activation in the LDTg, pica, the intake of non-nutritive substances and a well-
established model of nausea/malaise (Mitchell et al., 1977; Takeda et al., 1993; 
Yamamoto et al., 2002; Andrews and Horn, 2006; Kanoski et al., 2012a), was measured. 
Rats (n=8) were given access to kaolin clay (Research Diets, New Brunswick, NJ, USA) 
for ~1 week prior to the experiment. Chow and kaolin clay intake were measured at 24h 
after unilateral LDTg injection of exendin-4 (0, 0.025, 0.05µg; 100 nl aCSF). 
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 For meal pattern experiments, rats (n=10) were housed in a custom-made 
automated feedometer system consisting of hanging wire cages with access to a food 
cup on an electronic scale (Hayes et al., 2011b; Kanoski et al., 2012b; Mietlicki-Baase et 
al., 2013b), which records the weight of food cups every 10s through computer software 
(Labview). A meal was defined as at least 0.25g of food ingested with 10 minutes or 
more between feeding bouts (Hayes et al., 2011b; Kanoski et al., 2012b; Mietlicki-Baase 
et al., 2013b). Meal patterns were assessed at 12 and 24h post LDTg injection of 
exendin-4 (0, 0.025, 0.05µg; 100 nl aCSF). 
LDTg GLP-1R blockade feeding experiments 
 To determine the physiological role of GLP-1R signaling in the LDTg for energy 
balance control, we assessed the dose response of GLP-1R blockade in the LDTg on 
food intake and body weight gain. Rats (n=9) received unilateral LDTg injections of the 
competitive GLP-1R antagonist Ex-9 [0, 10, 20µg; 200 nl aCSF; doses chosen based on 
(Hayes et al., 2009)] immediately before the onset of the dark cycle. Food intake and 
body weight were measured. 
 To examine whether GLP-1R blockade in the LDTg attenuates the intake-
suppressive effects of voluntary ingestion of a nutritionally complete preload, rats (n=5) 
were trained to drink 9ml of vanilla Ensure® (Abbott Nutrition, Abbott Laboratories, 
Columbus, Ohio) in 15 min just prior to dark cycle onset. Immediately following the 
ingestion of Ensure®, rats received unilateral LDTg injections of Ex-9 (0, 10µg; 100 nl 
aCSF; dose chosen to be subthreshold for effect alone on feeding when administered in 
the LDTg) in a counter-balanced within subjects design. Injections were separated by at 
least 48h and following training, rats only received access to Ensure® on injection days. 
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Chow was removed during the 15min Ensure® access period and was given back 
immediately following the injection. Chow intake was measured at 0.5, 1, 1.5, 2, 4, and 
24h after injection, and body weight was measured at 0 and 24h after injection. 
 To examine whether acute pharmacological blockade of LDTg GLP-1R 
attenuates the intake-suppressive effects of systemic Ex-4 administration, we injected 
separate rats (n=9) with Ex-9 (0, 10µg; 100 nl aCSF; dose chosen to be subthreshold for 
effect alone on feeding when administered in the LDTg) unilaterally in the LDTg 1h prior 
to the onset of the dark cycle. Fifteen minutes prior to the onset of the dark cycle, rats 
were injected systemically with Ex-4 (3 µg/kg, IP), and subsequent food intake was 
measured. 
Statistical analyses 
 All data are represented as mean ± SEM with the α level set to p=0.05. Statistical 
analyses were performed using Statistica (Statsoft). For behavioral studies, binned data 
were analyzed using separate repeated measures one-way ANOVAs that accounted for 
the within-subjects experimental design. Statistically significant effects were probed 
using Student Neuman-Keuls post-hoc analyses or planned comparisons except when 
noted.
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Results 
LDTg GLP-1R activation reduces cumulative chow intake and body weight 
 As the LDTg expresses GLP-1R mRNA and receives projections from the NTS, a 
region that contains GLP-1-producing neurons (Cornwall et al., 1990; Merchenthaler et 
al., 1999), we first tested whether activation of GLP-1R in the LDTg suppresses food 
intake and body weight. Unilateral administration of Ex-4 in the LDTg decreases chow 
intake at 6 and 24h after injection compared to aCSF vehicle treatment (F2,18≥5.64, 
p<0.05; Figure 1A). Post-hoc analyses reveal that both doses of Ex-4 significantly 
suppress chow intake at 6 and 24h post-injection (p<0.05 compared to vehicle). Intra-
LDTg Ex-4 also significantly decreases 24h body weight change (F2,18=11.16, p<0.001; 
Figure 1B), with post-hoc analyses showing a significant effect with either dose of Ex-4 
(p<0.05 compared to vehicle). Importantly, behavioral data from animals (n=6) with 
missed LDTg cannula placements does not show hypophagia after GLP-1R activation 
(See Figure A2 in Appendix; F1,3<0.23, p>0.80). 
LDTg GLP-1R activation does not produce malaise 
 To determine if the intake suppression following LDTg GLP-1R activation is 
driven by nausea/malaise, we injected the same doses of Ex-4 into the LDTg and 
measured pica. Intra-LDTg significantly decreases 24h chow intake compared to vehicle 
(F2,14=3.91, p<0.05; Figure 1C) with post-hoc analyses showing that the higher dose of 
Ex-4 significantly reduces chow intake (p<0.05). Importantly, intra-LDTg has no effect on 
24h kaolin intake (F2,14=2.00, p<0.05; Figure 1D), suggesting that nausea/malaise is not 
driving the hypophagia following intra-LDTg GLP-1R activation. 
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LDTg GLP-1R activation suppresses meal size 
 Meal pattern analyses show that unilateral injection of Ex-4 in the LDTg 
significantly decreases meal size at 12h and 24h (F2,18>5.73, p<0.05; Figure 1E), but has 
no effect on meal number at either time point (F2,18<0.08, p>0.9; Figure 1F). Post-hoc 
analyses reveal that both doses of Ex-4 suppress meal size at 12 and 24h post-injection 
(p<0.05). These data suggest that LDTg GLP-1R activation reduces food intake 
predominantly through a reduction in meal size with minimal effects on meal number. 
GLP-1-expressing axon terminals are present in the LDTg, and NTS PPG neurons 
project to the LDTg 
 Central GLP-1 is produced by PPG neurons in the NTS, which project widely 
throughout the CNS, including to the VTA and NAc (Vrang et al., 2003; Alhadeff et al., 
2012; Grill and Hayes, 2012; Hayes et al., 2014b; Kanoski et al., 2016). We therefore 
performed immunohistochemical analyses to test whether GLP-1 axons are also present 
in the LDTg. Indeed, GLP-1-immunopositive axons are present in the LDTg (Figure 2A-
B). 
To directly determine the endogenous source of GLP-1 axons projecting into the 
LDTg, the retrograde tracer CTB was injected into the LDTg (n=3) and animals were 
sacrificed seven days later. Retrograde labeling of CTB shows that 4.9±1.0% of CTB-
immunopositive NTS neurons colocalize with PPG and 4.8±1.7% of PPG-
immunopositive neurons colocalize with CTB (see Figure 2C-E for representative 
images). A representative image shows that the CTB injection site from this same animal 
is within the LDTg (Figure 2F). These data provide evidence that a portion of NTS PPG 
neurons project to the LDTg. Collectively, IHC data showing the presence of GLP-1-
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immunopositive fibers in the LDTg and that NTS PPG neurons project to the LDTg 
provide anatomical evidence of a physiological role of endogenous GLP-1R signaling in 
the LDTg.  
LDTg GLP-1R blockade increases food intake 
 Intra-LDTg GLP-1R blockade with the competitive GLP-1R antagonist Ex-9 
significantly increases food intake (F2,16=3.64, p<0.05; Figure 3A) at 24h with no effect 
on body weight (F2,16=0.19, p=0.8; Figure 3B). Importantly, the 10µg dose of Ex-9 has no 
effect on food intake compared to aCSF vehicle (p>0.05), but the 20µg dose of Ex-9 
significantly increases food intake at 24h (p<0.05). These data suggest that GLP-1R 
signaling in the LDTg is physiologically relevant for food intake control. 
LDTg GLP-1R blockade attenuates the intake suppressive effects of a self-ingested 
preload 
 To determine the potential role of a gut-to-NTS-to-LDTg GLP-1 pathway in 
mediating food intake, we next examined if LDTg GLP-1R blockade can attenuate the 
intake suppressive effects of a voluntary ingested gastric preload (9 ml Ensure®) gastric 
distension. To avoid competing orexigenic and anorectic behavioral responses, we 
intentionally used a dose of Ex-9 that is subthreshold for an effect on feeding when 
delivered unilaterally in the LDTg. GLP-1R blockade in the LDTg significantly attenuates 
the intake suppressive effects of gastric distension at 2 and 24h post-injection (F1,4>8.76, 
p<0.05 Figure 3C) and approaches significance at 4h (F1,4=5.98, p=0.07). Intra-LDTg Ex-
9 also significantly increases body weight compared to aCSF vehicle treatment 
(F1,4=9.53, p<0.05; Figure 3D). These data show that LDTg GLP-1R blockade can 
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attenuate the intake suppressive effects of gastric distension, suggesting physiological 
relevance of either direct or indirect gut-to-LDTg signaling. 
Peripherally-administered fluorescent exendin-4 is juxtaposed with LDTg neurons 
Given that GLP-1 mimetics are administered systemically in humans, we next 
evaluated whether a peripherally-administered fluorescent GLP-1R agonist accesses the 
LDTg of rats. Indeed, systemically-administered FLEX shows juxtaposition with neurons 
but minimal association with astrocytes in the LDTg (Figure 4A-C). 
LDTg GLP-1R blockade attenuates the intake suppressive effects of a systemically-
administered GLP-1R agonist 
 Given anatomical data showing that a systemically-administered GLP-1R agonist 
accesses the LDTg, we next evaluated whether LDTg GLP-1R blockade attenuates the 
anorectic effects of systemic Ex-4. Systemic injection of Ex-4 significantly suppresses 
chow intake at 3h (main effect of Ex-4, F1,8=6.31, p<0.05) and approaches significance 
at 6h (main effect of Ex-4, F1,8=5.15, p=0.053) after injection (Figure 4C). There is also a 
significant interaction between Ex-4 and Ex-9 at 3 and 6h after injection (F1,8≥6.44, 
p<0.05); post-hoc analyses show that pre-treatment with intra-LDTg Ex-9 reverses the 
intake-suppressive effects of peripheral Ex-4 at 3h and 6h post-injection (p<0.05). 
Importantly, LDTg GLP-1R blockade alone (Ex-9/vehicle) does not significantly increase 
chow intake at any time point (all p>0.05 compared to vehicle/vehicle), though there is a 
significant main effect of Ex-9 at 3 and 6h (F1,8≥5.27, p<0.05) driven by the Ex-9/Ex-4 
condition. These data show that intra-LDTg GLP-1R blockade attenuates the 
hypophagic effects of systemically administered Ex-4, suggesting the potential pre-
clinical relevance of LDTg GLP-1R signaling.  Collectively, these behavioral data 
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complement the anatomical data in Figure 4A-B and highlight that peripherally 
administered Ex-4 accesses the LDTg in a functional capacity, suggesting the pre-
clinical relevance of GLP-1R signaling in the LDTg for energy balance control. 
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Discussion 
 To improve current obesity pharmacotherapies, research aimed at understanding 
neuroendocrine signals and the neurobiological substrates that control energy balance is 
required. Recently, much attention has been focused on the GLP-1 system, as GLP-1 
mimetics are FDA approved for diabetes and obesity treatment (Apovian et al., 2015; 
Kanoski et al., 2016). GLP-1R are widely expressed throughout the CNS, and central 
endogenous GLP-1, as well as exogenous long-lasting GLP-1R agonists activate these 
central GLP-1Rs, ultimately leading to reduced food intake and body weight (Kanoski et 
al., 2016). Given that GLP-1R are expressed widely throughout the CNS (Merchenthaler 
et al., 1999), it is important to examine the specific brain regions that mediate the effects 
of GLP-1R activation. The LDTg of the mesopontine tegmentum expresses GLP-1R 
(Merchenthaler et al., 1999), and has been shown to be a relevant nucleus for energy 
balance control and motivated behaviors (Schmidt et al., 2009; Dickson et al., 2010; 
Dickson et al., 2011; Lammel et al., 2012; Reiner et al., 2017). Here, we identify novel 
pharmacological and physiological roles of GLP-1R signaling in the LDTg for energy 
balance control. 
 Our data show that pharmacological activation of LDTg GLP-1Rs with direct 
intra-LDTg injection of the GLP-1R agonist Ex-4 decreases food intake and body weight, 
primarily through a reduction in meal size. These data are consistent with previous 
reports of central GLP-1R activation on energy balance that show similar magnitudes of 
intake suppression driven by reductions in meal size (Scott and Moran, 2007; Hayes et 
al., 2008; Grill and Hayes, 2009, 2012; Dossat et al., 2013; Hsu et al., 2015; Terrill et al., 
2016). Though peripheral administration of GLP-1 mimetics produces nausea/malaise 
(Kanoski et al., 2012a), our data show that direct LDTg GLP-1R activation does not 
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produce pica, suggesting an absence of nausea/malaise following activation of this 
population of central GLP-1Rs. Collectively, these behavioral data expand the known 
relevant CNS sites of action for GLP-1 signaling in mediating energy balance.  
 The current studies also support a physiological role for LDTg GLP-1R signaling 
in energy balance control. Acute blockade of LDTg GLP-1R increases food intake, and 
at a dose subthreshold for an effect on feeding, blockade of GLP-1R in the LDTg can 
attenuate the intake suppressive effects of a mixed macronutrient preload. Collectively, 
these data provide novel evidence of a physiological role for LDTg GLP-1R signaling in 
energy balance control and suggest that the LDTg receives communication from the gut 
either through a humoral mechanism or via a vagal-to-NTS-to-LDTg pathway. Given that 
gastric distension activates PPG neurons in the NTS (Vrang et al., 2003; Hayes et al., 
2009), combined with current data here showing that NTS PPG neurons project to the 
LDTg, the collective set of data would support the hypothesis that LDTg GLP-1 signaling 
mediates, at least in part, the satiation signaling arising from meal ingestion via a vagal-
NTS-LDTg pathway. Indeed, IHC data show that GLP-1-immunopositive axons are 
present in the LDTg and that NTS PPG neurons project to the LDTg, providing 
anatomical evidence that NTS PPG neurons project to the LDTg and likely release GLP-
1. Collectively, these data support a potential role of a gut-to-NTS-to-LDTg GLP-1 
pathway that mediates energy balance control. These data underscore that the LDTg is 
a critical site of action for endogenous GLP-1R signaling under physiological conditions. 
 As FDA-approved GLP-1 mimetics are given systemically, it is important to 
examine the CNS nuclei that are activated by these peripherally administered GLP-1R 
agonists. Behavioral data suggest that systemically delivered GLP-1R agonists access 
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the LDTg, as LDTg GLP-1R blockade attenuates the intake suppressive effects of 
peripherally administered Ex-4. Immunohistochemical data provide further evidence that 
systemically-delivered GLP-1R agonists access the LDTg. Given the lack of a 
commercially available GLP-1R-specific antibody, we used peripheral administration of 
fluorescently-labeled Ex-4 to label GLP-1R-expressing cells (Reiner et al., 2016; Terrill 
et al., 2016). These data show that a systemically-delivered GLP-1 mimetic resistant to 
enzymatic degradation can access the LDTg, highlighting the potential pre-clinical 
relevance of the GLP-1R LDTg system. Interestingly, in contrast with our previous study 
showing FLEX localized to and internalized in both neurons and astrocytes within the 
NTS after IP administration (Reiner et al., 2016), FLEX associates predominately with 
neurons in the LDTg but only very minimally with LDTg astrocytes. These data indicate 
that GLP-1R may be expressed on different cell types depending on the CNS nucleus. 
Future investigation should examine the differential pharmacokinetics and receptor-
binding rates throughout GLP-1R-expressing nuclei and how these cell types/regions 
might modulate energy balance, nausea, glycemic control, and motivated behaviors. 
 Collectively, our data show that LDTg GLP-1R signaling is pharmacologically and 
physiologically relevant for energy balance control and provide novel evidence of gut-
NTS-LDTg GLP-1 signaling. Given that the LDTg is anatomically connected to feeding-
relevant nuclei in the hindbrain, midbrain, hypothalamus, and forebrain (Cornwall et al., 
1990), the current set of findings highlight the importance of investigating the LDTg and 
its role in integrating information from a wide range of CNS regions in order to mediate 
energy balance. Future studies should also explore how GLP-1 signaling in the LDTg 
interacts with other energy balance relevant signals to control energy balance as well as 
motivated behavior. Importantly, behavioral and anatomical data show that systemically 
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delivered long-acting GLP-1 mimetics can access the LDTg and regulate food intake, 
suggesting that the LDTg is of potential pre-clinical relevance for GLP-1-mediated 
energy balance control. 
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Figure 1. Intra-LDTg GLP-1R activation suppresses food intake through a 
decrease in meal size and independent of nausea. The GLP-1R agonist Ex-4 was 
unilaterally injected in the LDTg in a counterbalanced within-subjects design (n=10) at 
the onset of the dark cycle using the following doses: 0 (aCSF), 0.025, or 0.05µg. These 
doses of Ex-4 suppress food intake at 6 and 24h (A) and also reduce 24h body weight 
change (B). To determine if LDTg GLP-1R activation produces nausea/malaise, kaolin 
intake was measured following unilateral Ex-4 LDTg administration. A separate cohort of 
animals (n=8) received access to both chow and kaolin clay for one week prior to the 
beginning of the experiment. Intra-LDTg Ex-4 decreases 24h food intake (C) but has no 
effect on 24h kaolin intake (D). Meal patterns were analyzed in a third cohort of animals 
(n=10). Ex-4 decreases 12 and 24h meal size (E) but had no effect on meal number (F). 
* indicates significance by repeated measures ANOVA (p<0.05). Different letters are 
significantly different from each other (p<0.05) according to post-hoc tests. The key in 
(A) applies to all panels. 
 
72 
	
Figure 2. GLP-1-positive axons are present in the LDTg, and PPG neurons project 
from the NTS to the LDTg. Immunolabeling shows the presence of GLP-1-positive 
axons in the LDTg (n=4). Representative images are shown in (A-B). The white dashed-
line box in A indicates the field of view in B. To determine if the NTS PPG neurons 
project to the LDTg, rats (n=3) were unilaterally injected with the neural pathway tracer 
CTB in the LDTg. Seven days later, rats were perfused and their brains were processed. 
Within the NTS, 4.9±1.0% of retrogradely-labeled CTB-positive neurons (green) co-
localize with PPG-positive neurons (red). Representative images show CTB-positive 
neurons in green (C), PPG-positive neurons in red (D), and merged in (E). Figure 4F 
shows a representative CTB LDTg injection site. The white arrows in E indicate co-
localization (yellow). 4V = 4th ventricle, cc= central canal, LDTg = lateral dorsal 
tegmental nucleus, NTS = nucleus tractus solitarius. 
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Figure 3: LDTg GLP-1R blockade increases food intake and attenuates the intake 
suppressive effects of a self-ingested preload. To determine the effect of GLP-1R 
blockade in the LDTg on food intake, the competitive GLP-1R antagonist Ex-9 was 
injected unilaterally in the LDTg in a counterbalanced within-subjects design at the onset 
of the dark cycle using the following doses: 0 (aCSF), 10, 20µg; 200nl (n=9). Only the 
highest dose of Ex-9 (20µg) increases food intake at 24h (A) and neither dose of Ex-9 
had an effect on 24h body weight change (B). To determine if LDTg GLP-1R blockade 
can attenuate the hypophagic effects of gastric distension, rats (n=5) were trained to 
drink 9ml of Ensure® in fifteen minutes just prior to dark cycle onset. Following stable 
intake of Ensure®, rats received unilateral LDTg injections of Ex-9 [0 (aCSF), 10µg; 100 
nl aCSF] immediately after the fifteen-minute Ensure® access period in a within-subjects 
design. Ex-9 significantly increases food intake at 2 and 24h after injection (C) and body 
weight over 24h (D).  * indicates significance (p<0.05) and # indicates a trend for 
significance (p=0.07) by repeated measures ANOVA. Different letters are significantly 
different from each other (p<0.05) according to post-hoc tests. The key in (A) applies to 
(B), and the key in (C) also applies to (D). 
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	Figure 4: Systemically-delivered GLP-1R agonists access the LDTg. To determine 
if peripherally administered Ex-4 penetrates the LDTg, we injected fluorescently-tagged 
Ex-4 (FLEX, 3 µg/kg, IP), perfused the rats (n=5) 3h later, and processed the LDTg to 
visualize neurons, astrocytes, and FLEX. Peripherally administered FLEX (green) is 
juxtaposed with neurons (red) but minimally with astrocytes (blue) within the LDTg (A-B). 
63x image in A, and 3x optical zoom of 63x in B. Dotted rectangle in A indicates field of 
view in B and C (still from 3D rotational video). To determine if GLP-1R blockade in the 
LDTg attenuates the hypophagic effects of peripheral Ex-4, the competitive GLP-1R 
antagonist Ex-9 was unilaterally injected in the LDTg (n=9) at a dose subthreshold for an 
effect on feeding (10µg; vehicle, 100nl aCSF) approximately 1h prior to the onset of the 
dark cycle. Fifteen minutes prior to the onset of the dark cycle, rats were injected 
systemically with Ex-4 [0 (saline), 3 µg/kg]. Ex-4 significantly suppresses food intake at 
3h (p<0.05) and approaches significance at 6h post-injection (p=0.06), and pre-
treatment with Ex-9 reverses this intake suppression (D). * indicates significant main 
effect of Ex-4 significance (p<0.05).  † indicates a significant main effect of Ex-9 
(p<0.05). ‡ indicates a significant interaction between Ex-4 and Ex-9 (p<0.05). Different 
letters are significantly different from each other (p<0.05) according to post-hoc tests.  
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Abstract 
 The pancreatic- and brain-derived hormone amylin promotes negative energy 
balance and is receiving increasing attention as a promising obesity therapeutic. 
However, the neurobiological substrates mediating amylin’s effects are not fully 
characterized. We postulated that amylin acts in the lateral dorsal tegmental nucleus 
(LDTg), an understudied neural-processing hub for reward and homeostatic feeding 
signals. We used immunohistochemical (IHC) and quantitative PCR analyses to 
examine expression of the amylin receptor complex in rat LDTg tissue. Behavioral 
experiments were performed to examine the mechanisms underlying the hypophagic 
effects of amylin receptor activation in the LDTg. IHC and quantitative PCR analyses 
show expression of the amylin receptor complex in the LDTg. Activation of LDTg amylin 
receptors by the agonist salmon calcitonin dose-dependently reduces body weight, food 
intake, and motivated feeding behaviors. Acute pharmacological studies and longer-term 
adeno-associated viral (AAV)-knockdown experiments indicate that LDTg amylin 
receptor signaling is physiologically and potentially pre-clinically relevant for energy 
balance control. Finally, IHC data indicate that LDTg amylin receptors are expressed on 
gamma-aminobutyric acid (GABA)-ergic neurons and behavioral results suggest that 
local GABA receptor signaling mediates the hypophagia following LDTg amylin receptor 
activation. These findings identify the LDTg as a novel nucleus with therapeutic potential 
in mediating amylin’s effects on energy balance through GABA receptor signaling. 
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Introduction 
 In the search for effective pharmacological treatments for obesity, much attention 
has focused on neuroanatomical targets in the central nervous system (CNS) such as 
the hypothalamus and caudal brainstem, each historically linked with the homeostatic 
regulation of energy balance (Grill, 2006; Lutz, 2006; Moran, 2009; Moran and 
Ladenheim, 2011; Grill and Hayes, 2012; Merlino et al., 2014). While these studies have 
informed the field about cellular and molecular mechanisms mediating the metabolic 
effects of many gastrointestinal- and adipose tissue-derived hormones, the chronic 
hyperphagia underlying human obesity does not appear to be related to disproportionate 
homeostatic feeding, but rather is more likely based on excessive appetitive and 
motivational processes directed towards the consumption of highly palatable/rewarding 
food (Lutter and Nestler, 2009; Halford et al., 2010; Kenny, 2011; Berthoud, 2012). 
Indeed, targeting non-homeostatic/reward-based systems may provide a unique 
opportunity to treat obesity and metabolic diseases (Narayanan et al., 2010; DiLeone et 
al., 2012). Urgently needed, however, is a deeper understanding of the relevant CNS 
reward circuitry and how it responds to and integrates energy balance signals to control 
food intake and body weight. 
The lateral dorsal tegmental nucleus (LDTg) is a nucleus in the mesopontine 
tegmentum that is uniquely positioned as a processing hub for the integration of reward-
based and homeostatic energy balance signaling (Cornwall et al., 1990; Schmidt et al., 
2009; Dickson et al., 2011), yet has been understudied for its role in feeding and other 
motivational processes. Indeed, the LDTg has reciprocal projections with many feeding-
relevant nuclei throughout the neuraxis, including but not limited to, the nucleus tractus 
solitarius (NTS), the ventral tegmental area (VTA), the lateral hypothalamus (LH), and 
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the parabrachial nucleus (PBN) (Cornwall et al., 1990). Given that the LDTg expresses 
receptors for a variety of feeding peptides (e.g. amylin, glucagon-like peptide-1, ghrelin, 
oxytocin, orexin and PYY) (Sexton et al., 1994; Merchenthaler et al., 1999; Parker and 
Herzog, 1999; Greco and Shiromani, 2001; Gould and Zingg, 2003; Dickson et al., 2011; 
Cabral et al., 2013), we hypothesize that energy balance-relevant neuroendocrine 
signals may act directly in the LDTg to modulate the neural processing of feeding-
relevant information and affect motivational aspects of food reward. 
Following initiation of a meal, a cascade of endocrine events occurs, including 
secretion of the peptide hormone amylin from the pancreatic β cells. Amylin activates its 
receptors within the CNS to suppress ongoing feeding during the meal and increase 
satiation (Roth et al., 2009; Lutz, 2012). Historically, the contribution of central amylin 
signaling to food intake control has centered on its action in homeostatic feeding 
centers, primarily the area postrema (AP) of the caudal brainstem (Lutz et al., 1998b; 
Lutz et al., 2001; Lutz, 2010b, a; Potes and Lutz, 2010; Potes et al., 2010; Potes et al., 
2012; Roth et al., 2012), and secondarily in hypothalamic subnuclei including the arcuate 
nucleus (ARH) and ventromedial hypothalamus (VMH) (Trevaskis et al., 2010; Turek et 
al., 2010; Dunn-Meynell et al., 2016). However, recent work has also established the 
VTA and nucleus accumbens (NAc) as relevant nuclei for amylin’s energy balance 
effects, particularly for reward-based feeding (Mietlicki-Baase et al., 2013b; Baisley and 
Baldo, 2014; Mietlicki-Baase et al., 2015b). While this growing body of literature 
highlights a more distributed CNS system mediating amylin’s energy balance effects 
than originally thought, the action of amylin in these aforementioned nuclei cannot wholly 
explain the energy balance and food reward effects of amylin signaling (Lutz et al., 
1998b; Mack et al., 2007; Mack et al., 2010). In fact, as the neural control of energy 
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balance is distributed across the CNS (Grill and Kaplan, 2002; Grill and Hayes, 2012) 
and in vitro radiography studies show that amylin binds to sites throughout the brain 
(Sexton et al., 1994; Becskei et al., 2004), the ability of amylin receptor signaling in other 
CNS nuclei to produce hypophagia requires more extensive evaluation.  
Given that amylin is currently being considered as an anti-obesity therapeutic, it 
is especially critical to more fully understand the neural substrates mediating amylin’s 
effects on reward-based feeding in addition to its impact on homeostatic intake (Lutz, 
2012; Roth, 2013; Sadry and Drucker, 2013; Mietlicki-Baase and Hayes, 2014; Hay et 
al., 2015). That the LDTg binds amylin (Sexton et al., 1994) and is widely connected with 
a variety of energy balance-relevant nuclei (Cornwall et al., 1990), collectively supports 
our hypothesis that amylin receptor signaling in the LDTg may control food intake, body 
weight, and motivated behaviors directed towards food reward. Thus, data presented 
here lend greater insight into amylin receptor signaling through the CNS by identifying 
the LDTg as a novel nucleus mediating the anorexigenic effects of amylin, while 
underscoring the LDTg GABAergic system as a potential target for amylin-based 
therapies for the treatment of obesity. 
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Materials and Methods 
Animals 
 Male Sprague-Dawley rats (310-325g upon arrival; Charles River, Wilmington, 
MA, USA) were individually housed in hanging wire cages (12h light/dark cycle) and had 
ad libitum access to chow (Purina LabDiet 5001, Quakertown, PA, USA) and water 
unless otherwise noted. For experiments labeling GABAergic neurons, male Sprague-
Dawley rats (250g upon arrival; Envigo Labs, Indianapolis, IN, USA) were individually 
housed in hanging wire cages (12h light/dark cycle) and had ad libitum access to food 
and water. All procedures were approved by the Institutional Animal Care and Use 
Committee at University of Pennsylvania or University of Southern California and were 
performed according to the National Institutes of Health guidelines. 
Drugs 
 The amylin receptor agonist salmon calcitonin (sCT; Bachem, Torrance, CA, 
USA) was dissolved in artificial cerebrospinal fluid (aCSF; Harvard Apparatus, Holliston, 
MA, USA) for central injections or 0.9% sterile saline for peripheral injections. Amylin 
(Bachem Torrance, CA, USA), the amylin receptor antagonist AC187 (R&D Systems, 
Minneapolis, MN, USA), and saclofen (Sigma Aldrich, St. Louis, MO, USA) were 
dissolved in aCSF. Bicuculline (Sigma Aldrich, St. Louis, MO, USA) was dissolved in 
50% DMSO in aCSF-0.1M NaOH. 
Stereotaxic surgery 
 Animals were anesthetized with a cocktail (KAX) composed of ketamine 
(90mg/kg), acepromazine (0.64mg/kg), and xylazine (2.7mg/kg; IM), and placed into a 
stereotaxic apparatus. Bilateral guide cannulae (Plastics One, Roanoke, VA, USA) 
targeting the LDTg (coordinates: ±0.5mm lateral to midline, 8.7 mm posterior to bregma, 
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4.1 mm ventral to skull; injector aimed 6.6 mm ventral to skull) were implanted and 
affixed to the skull with bone screws and dental cement. Analgesia was provided for all 
surgeries (meloxicam, 2 mg/kg). Rats were allowed ~1 week recovery from surgery 
before the beginning of an experiment. LDTg injection placements were verified 
histologically postmortem by either visualization of green fluorescent protein (GFP) in the 
calcitonin receptor (CTR) knockdown experiment or by intraparenchymal injections of 
pontamine sky blue (100 nl) in all other behavioral experiments. Animals with missed 
cannula placements were eliminated from analyses.  
For lateral ventricle cannulae placements, rats were deeply anesthetized with a 
KAX cocktail composed of ketamine (90 mg/kg), acepromazine (0.72 mg/kg), and 
xylazine (2.8 mg/kg; IM), and placed in a stereotaxic apparatus. A stainless steel guide 
cannula (26-gauge Plastics One, Roanoke, VA) was surgically implanted toward the 
lateral ventricle using the following coordinates: 1.8mm lateral to bregma, 0.9 mm 
posterior to bregma, and 2.6 mm ventral from the surface of the skull, injector aimed 4.6 
mm ventral from the skull. Following one week of recovery, placement of the cannula 
was verified by the elevation of cytoglucopenia resulting from a single injection of 2 µl of 
105µg/µl 5-thio-D-glucose (Ritter et al., 1981). Animals that did not have at least 100% 
elevation of baseline blood glucose by 2 hours post injection were not used for 
colchicine injections. 
Quantitative PCR 
 Chow-maintained rats (n=6) were euthanized 1-2h into the dark phase. Brains 
were rapidly removed, flash-frozen in −70 °C isopentane, and stored at −80 °C until 
processing. To examine the relative expression of the components of amylin receptor 
 
82 
	
complex in the LDTg via quantitative real-time PCR (qPCR), bilateral 1 mm3 
micropunches/hemisphere of LDTg-enriched tissue (approximately 8.2-9.2 mm posterior 
to bregma) were collected from each brain. Tissue samples were processed for the gene 
expression of components of the amylin receptor, the CTR and receptor activity 
modifying protein (RAMP) as previously described (Mietlicki-Baase et al., 2013b). Total 
RNA was extracted from the tissue samples using TRIzol (Invitrogen, Grand Island, NY, 
USA) and the RNeasy kits (Qiagen, Valencia, CA, USA) and used to synthesize cDNA 
with the Advantage RT-for-PCR kit (Clontech, Mountain View, CA, USA). Relative 
mRNA expression of each CTR and RAMP subtype was quantified using Taqman gene 
expression kits (CTR-A: Rn01526770_m1, CTR-B: Rn01526768_m1, RAMP1: 
Rn01427056_m1, RAMP2: Rn00571815_m1, RAMP3: Rn00824652_g1, GapDH: 
Rn01775763_g1) and PCR reagents from Applied Biosystems (Grand Island, NY, USA). 
Samples were analyzed with the Eppendorf Mastercycler ep realplex2. Relative mRNA 
expression calculations were completed using the comparative threshold cycle method 
(Bence et al., 2006; Mietlicki-Baase et al., 2013b). One sample was eliminated due to a 
technical error during RNA isolation. 
Immunohistochemical analyses  
 Rats were deeply anesthetized with an IM injection of the surgical dose of KAX 
used for the LDTg cannulation surgeries and transcardially perfused with 0.1 M PBS, 
followed by 4% paraformaldehyde in 0.1 M PBS. Brains were removed, postfixed in 4% 
paraformaldehyde for 6h and subsequently cryoprotected in 20% sucrose in 0.1 M PBS 
at 4°C for ~3 days. Brains were sectioned coronally (30 µm) with a cryostat. Sections 
were blocked in 0.1M PBS with 5% donkey serum and 0.2% Triton-X at room 
temperature and incubated in primary antibodies overnight in 5% normal donkey serum 
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with 0.2% Triton-X. The following primary antibodies used were at a 1:1000 dilution: 
rabbit anti-CTR (ab11042, Abcam, Cambridge, MA, USA), mouse anti-NeuN (MAB377, 
Millipore, Billerica, MA, USA), chicken anti-glial fibrillary acidic protein (GFAP, AB5541, 
Millipore, Billerica, MA, USA), and goat anti-choline acetyltransferase (ChAT, AB144P, 
Millipore, Billerica, MA, USA) (Wang and Morales, 2009; Lopez et al., 2012; Mietlicki-
Baase et al., 2015b; Saunders et al., 2015). Following a PBS rinse, sections were 
incubated in appropriate donkey Alexa Fluor 488, 594, and AMCA secondary antibodies 
(Jackson Immunoresearch, West Grove, PA, USA) at room temperature (all secondary 
antibodies 1:500 in 5% normal donkey serum with 0.2% Triton-X). Sections were 
mounted on slides and visualized with a Leica SP5 X confocal microscope using 
objectives and the 405, 488, and 594 laser lines. All images were collected sequentially 
to avoid contamination of signals from other fluorophores. 
Colchicine treatment and co-localization of CTR and GABAergic markers 
 To enhance labeling for glutamate decarboxylase 67 (Gad67), a GABAergic 
marker, a rat (n=1) was injected with colchicine (400µg, dissolved in 4µl of DMSO), a 
neurotoxin that blocks neurotransmission, directly in the lateral ventricle (Halasy et al., 
2004; Wang et al., 2014). Twenty-eight hours after colchicine treatment, the rat was 
anesthetized with the surgical dose of KAX used in the lateral ventricle cannulation, 
perfused transcardially with ice-cooled 0.9% saline, followed by 4% paraformaldehyde in 
0.1 M borate buffer of pH 9.5. The brain was removed and immersed in 4% 
paraformaldehyde containing 12% sucrose for 20–24h at 4oC. The brain was then 
blocked transversely at the level of the caudal midbrain, and the block was flash-frozen 
in dry-ice cooled hexane before being sectioned frozen on a sliding microtome 
(transverse plane, 30 µm thickness, 5 series). Sections were stored in antifreeze solution 
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(30% ethylene glycol, 20% glycerol in 0.02 M potassium phosphate-buffered saline—
KPBS) at -20 ̊C until further processing. Sections were incubated in primary antibodies 
at 4oC overnight in KPBS containing 1% donkey serum and 0.1% Triton X-100. The 
following primary antibodies were used: rabbit anti-CTR (1:1000, ab11042, Abcam, 
Cambridge, MA, USA) and mouse anti-GAD67 (1:10000, MAB5406, Millipore, Billerica, 
MA, USA) (Deidda et al., 2015; Mietlicki-Baase et al., 2015b). Following washes in 
KPBS, sections were incubated in appropriate secondary antibodies at 4oC overnight 
diluted at 1:500 in KPBS containing 0.1% Triton X-100 (donkey AffiniPure Cy3 and Alexa 
Fluor 488, Jackson Immunoresearch, West Grove, PA, USA). Following washes in 
KPBS, sections were mounted onto glass slides, allowed to dry, and coverslipped, using 
50% glycerol in KPBS mountant. Coverslip edges were sealed with clear nail polish. 
Photomicrographs were acquired as optical slices using a Zeiss LSM 700 UGRB 
Confocal System (controlled by Zeiss Zen software). All photomicrographs in the figures 
are oriented such that: up = dorsal, down = ventral, left = medial, right = lateral. 
Behavioral testing 
General procedures 
 Drug injections were made just prior to the onset of the dark cycle unless 
otherwise specified. For experiments measuring ad libitum food intake, weights of food 
hoppers were recorded to the nearest 0.1g and food spillage is accounted for in 
cumulative food intake measurements. Food intake was recorded at 1, 3, 6, and 24h 
after injection, while body weight was measured at 0 and 24h after injection, except 
where noted. Injections were administered using a within-subjects counterbalanced 
design and were separated by at least 72h. 
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Intra-LDTg amylin and salmon calcitonin dose-response feeding experiments 
 To assess the dose-response of amylin receptor activation in the LDTg on food 
intake and body weight gain, rats (n=10) received unilateral LDTg injections of amylin (0, 
0.2, 0.4, and 0.8µg; 100 nl aCSF) shortly before the onset of the dark cycle. The doses 
of amylin for this experiment were selected based on previous dose response 
experiments in the 3rd ventricle and VTA (Rushing et al., 2000; Mietlicki-Baase et al., 
2015a). In order to compare the hypophagic effects of LDTg administration of amylin 
with the long acting amylin receptor agonist sCT, we injected sCT unilaterally into the 
LDTg just before the onset of the dark cycle in a separate cohort of rats (n=6). The sCT 
doses for this series of experiments (0, 0.01, 0.04, and 0.1µg; 100 nl aCSF) were 
selected based on previous dose response experiments in the 3rd ventricle and VTA 
(Mietlicki-Baase et al., 2013b). Given that previous studies have shown that lower doses 
of sCT are required to produce a feeding effect compared to amylin (Lutz et al., 2000; 
Mietlicki-Baase et al., 2013b; Mietlicki-Baase et al., 2015a; Mietlicki-Baase et al., 2015b), 
the doses of amylin were considerably lower than that of sCT. 
 For meal pattern experiments, rats (n=5) were housed in a custom-made 
automated feedometer system that consists of hanging wire mesh cages with a small 
hole allowing access to a food cup that rests on an electronic scale (Hayes et al., 2011b; 
Kanoski et al., 2012b; Mietlicki-Baase et al., 2013b). Computer software (LabView) 
recorded the weights of the food cups every 10s for 24h. A meal was defined as at least 
0.25g of food intake with at least 10 minutes in between feeding bouts (Hayes et al., 
2011b; Kanoski et al., 2012b; Mietlicki-Baase et al., 2013b). Meal patterns were 
assessed at 24h post-LDTg injection (0, 0.01, 0.04, or 0.1µg sCT). 
 
86 
	
 To test if nausea/malaise contributes to the intake suppression following LDTg 
amylin receptor activation by measuring pica, rats (n=6) were given access to both chow 
and kaolin clay (Research Diets, New Brunswick, NJ, USA) for ~1 week prior to the 
experiment. Chow intake, kaolin clay intake, and body weight were measured at 24h 
after injection of sCT (0, 0.01, 0.04, or 0.1µg) into the LDTg.  
Intra-LDTg amylin receptor activation sucrose self-administration experiment 
 Experiments were conducted in ventilated, sound-attenuating operant chambers 
(Med Associates, St Albans, VT, USA). Rats (n=8) were initially food restricted to ~80% 
of daily intake and trained to lever press for 45 mg sucrose pellets (Research Diets) on a 
fixed ratio 1 (FR1) schedule of reinforcement during 1 h operant sessions. Once animals 
achieved stable responding for sucrose (defined as <20% variation in responding over 
three consecutive days) on the FR1 schedule of reinforcement, the response 
requirement was increased to FR3 for two days, followed by three days on FR5. Animals 
were then given access to ad libitum chow and maintained on FR5 for an additional 
seven days. Motivation to self-administer sucrose pellets was then assessed using a 
progressive ratio (PR) schedule of reinforcement. Under a PR schedule, the response 
requirement for the ith reinforcement of each subsequent delivery of a sucrose pellet 
increases exponentially, according to the formula R(i) = [5e0.2i – 5], until the rat fails to 
meet the requirement in a 30 minute time period (Hopkins et al., 2012). Using a within-
subjects design, rats were injected with aCSF (100 nl), amylin (0.4µg; 100 nl), or sCT 
(0.04µg; 100 nl) into the LDTg 30 minutes prior to a PR self-administration test session. 
We chose these doses based on previous literature showing that lower doses of sCT are 
needed to produce a feeding effect compared to amylin (Lutz et al., 2000; Mietlicki-
Baase et al., 2013a; Mietlicki-Baase et al., 2015a; Mietlicki-Baase et al., 2015b). 
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Treatments were counterbalanced and test days were separated by at least 2 days of 
responding for sucrose on the FR5 schedule of reinforcement. The responding of one rat 
declined prior to completion of the experiment due to equipment malfunction, and he 
was subsequently removed from behavioral analyses. 
Intra-LDTg acute amylin receptor blockade feeding experiment 
 We examined whether acute pharmacological blockade of LDTg amylin receptors 
was sufficient to attenuate the intake suppressive effects of a systemic sCT injection. 
The amylin receptor antagonist, AC187, was bilaterally injected in the LDTg 
(0.8µg/100nl/hemisphere; dose chosen from pilot experiments to be subthreshold for 
food intake effect on its own) 1h prior to the onset of the dark cycle (Mietlicki-Baase et 
al., 2013b). Fifteen minutes prior to the onset of the dark cycle, rats (n=11) were injected 
systemically with the amylin receptor agonist, sCT (5 µg/kg, IP), and subsequent food 
intake and body weight were measured.  
Intra-LDTg amylin receptor knockdown experiment 
 A validated AAV1-shRNA construct for CTRa/b knockdown was used as 
previously described (Mietlicki-Baase et al., 2015b). Rats were maintained on chow for 1 
week prior to surgery to establish baseline intakes and body weight and were divided 
into two weight-matched groups. Animals were assigned to receive a bilateral LDTg 
injection (200 nl/hemisphere) of either an AAV control vector expressing GFP (AAV-
Control, n=7) or the AAV-shRNA for the CTR-a/b expressing GFP (AAV-CTR KD, n=7). 
Beginning post-surgery day 1, food intake, food spillage and body weight were 
measured every 48h for a total of 30 days (days 1-31 post-viral injection). One rat was 
removed from the behavioral analyses due to technical errors in data collection. After 
conclusion of the behavioral study, rats were anesthetized with a surgical dose of KAX 
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used in the LDTg cannulation (IM) and euthanized by decapitation. The brains were 
rapidly removed and flash frozen. Correct placement of AAV injections was verified by 
collecting a section containing the LDTg (30 µm) from each brain and visualizing GFP. 
Micropunches of the LDTg were collected and the LDTg CTRa knockdown was 
confirmed with qPCR, with GapDH as the internal control.  
Intra LDTg GABA receptor blockade feeding experiment 
 To test the role of GABA receptors in mediating LDTg amylin-mediated intake 
suppression, a cocktail composed of bicuculline (GABA-A receptor antagonist, 100 ng; 
100 nl) and saclofen (GABA-B receptor antagonist, 500 ng; 100 nl) was unilaterally 
injected in the LDTg (100 nl, 50% DMSO in aCSF) 30 minutes prior to the onset of the 
dark cycle. Fifteen minutes prior to the onset of the dark cycle, rats (n=8) were 
unilaterally injected with sCT (0.04µg; 100 nl, aCSF vehicle) in the ipsilateral LDTg, and 
food intake and body weight were measured. 
Statistical Analyses 
 All data are represented as mean ± SEM. The α level was set to p≤0.050 for all 
studies. Statistical analyses were performed using Statistica 13.0 (StatSoft). For all 
feeding and body weight studies, binned data were analyzed using separate repeated 
measures ANOVAs that accounted for the within-subjects experimental design, while 
assessing between-subjects effects (drug treatment, AAV condition) when applicable, 
except when noted. Body weight for the GABA-A/B receptor blockade experiment was 
analyzed as a repeated measures one-way ANOVA. Sucrose self-administration was 
analyzed using separate ANOVAs for each behavioral measure, accounting for the 
within-subject experimental design. CTR/RAMP expression was analyzed, relative to 
CTRb and RAMP3, using separate ANOVAs for each gene that accounted for the within-
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subject experimental design. For the CTR knockdown experiment, gene expression was 
analyzed using an ANOVA that accounted for the between-subject experimental design. 
Statistically significant effects were probed using Student-Neuman-Keuls post hoc 
analyses or planned comparisons when noted. 
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Results 
The components of the amylin receptor complex are expressed in the LDTg 
 Amylin receptors are formed by heteromeric interaction between one of two 
Gs/Gq-coupled calcitonin receptors (CTRa or CTRb) and one of three receptor activity-
modifying proteins (RAMP1-3) (Poyner et al., 2002; Morfis et al., 2008). Although the 
LDTg binds amylin (Sexton et al., 1994), no studies to date have examined expression 
of the amylin receptor complex within this nucleus. Therefore, we used quantitative real-
time PCR to determine expression of the components of the amylin receptor (CTRa/b, 
RAMP1-3) in the LDTg, and found that both CTRs and all three RAMPs are indeed 
expressed in this nucleus (n=6). CTRa gene expression is approximately 5-fold greater 
than expression of CTRb, although this does not reach statistical significance (F1,3=4.04, 
p=0.14; Figure 1A). Gene expression of RAMP1 is approximately 2-fold greater than the 
expression of RAMP2 (F2,6=13.04, p<0.01; posthoc test, p<0.05) and approximately 13-
fold greater than the expression of RAMP3 (posthoc test, p<0.01; Figure 1B). These 
findings are consistent with data from the AP and VTA, which also show higher 
expression of CTRa compared to CTRb and abundant RAMP1 expression (Lutz, 2012; 
Mietlicki-Baase et al., 2013b).  
Next, we performed immunohistochemical (IHC) analyses to label cells that 
express CTR (n=6). Our data show labeling throughout the rostral-caudal axis of the 
LDTg, with particularly dense labeling in the caudal LDTg (8.6-9.1mm posterior to 
bregma), providing evidence of amylin receptor expression at the protein level. 
Representative images from the caudal LDTg are shown in Figure 1C-D. Together, data 
in Figure 1 show that components of the amylin receptor complex are expressed in the 
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LDTg at the gene and protein levels. Due to the dense CTR expression observed in the 
caudal LDTg, we targeted this subregion in our behavioral experiments. 
LDTg amylin suppresses cumulative chow intake and body weight 
 As all components of the amylin receptor are expressed in the LDTg, this nucleus 
may mediate, in part, the negative energy balance effects of amylin. To test whether 
activation of amylin receptors in the LDTg by the native amylin peptide is sufficient to 
decrease food intake, rats (n=10) were unilaterally injected in the LDTg with amylin (0, 
0.2, 0.4, and 0.8µg; 100 nl aCSF; see Figure 2A for representative injection placement) 
and subsequent chow intake and body weight change were recorded over a 24h period. 
Injection of amylin in the LDTg dose-dependently decreases food intake over 6h 
(F3,27≥3.00, p<0.05; Figure 2B) but not 24h food intake or body weight change 
(F3,27≤2.32, p>0.05; Figure 2C). Consistent with previous reports of amylin-induced 
hypophagia at early time points (Lutz et al., 1998a; Mietlicki-Baase et al., 2015a), all 
doses of amylin administered to the LDTg suppress chow intake at 1h (p<0.01), but only 
the highest dose of amylin (0.8µg) suppresses chow intake at 3 and 6h after injection 
(p<0.05) compared to aCSF treatment.  
LDTg amylin receptor activation suppresses cumulative chow intake and body weight 
 To determine whether pharmacological LDTg amylin receptor activation with the 
long-acting amylin receptor agonist sCT produces more durable and more potent 
hypophagic effects, sCT (0, 0.01, 0.04, or 0.1µg), was injected unilaterally into the LDTg 
and subsequent chow intake and body weight change were recorded over a 24h period 
(n=6). Notably, the two lower doses of sCT, 0.01 and 0.04 µg, are subthreshold for 
prolonged effects on food intake and body weight when applied to the 3rd ventricle 
(Mietlicki-Baase et al., 2013b). Results of this study show that intra-LDTg amylin 
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receptor activation with sCT dose-dependently suppresses chow intake at 1, 3, 6, and 
24h after injection (F3,12≥3.66, p<0.05; Figure 2B). Post-hoc analyses reveal that all 3 
doses of sCT produce a significant suppression of chow intake, compared to aCSF 
vehicle treatment, at 1h (p<0.01) and 6h (p<0.05) after injection. Additionally, the two 
highest sCT doses (0.04 and 0.1 µg) decrease food intake at 24h after injection 
(p<0.05). Body weight gain over the 24h post-injection is also significantly reduced by 
intra-LDTg administration of 0.04 or 0.1 µg sCT (F3,12=11.00, p<0.01; compared to 
aCSF, p<0.05; Figure 2C). These data indicate that LDTg amylin receptor activation 
dose-dependently suppresses chow intake and body weight over 24h. Importantly, 
behavioral data from animals (n=3) with missed LDTg cannula placements does not 
show hypophagia after amylin receptor activation (See Figure A3 in Appendix; (F1,3<0.6, 
p>0.64). Taken together and consistent with previous literature (Lutz et al., 2000; 
Reidelberger et al., 2002), LDTg amylin receptor activation with sCT results in more 
potent and longer-lasting hypophagic effects than LDTg administration of native peptide 
amylin. 
LDTg amylin receptor activation suppresses meal size 
 To evaluate the behavioral mechanisms driving the hypophagia following LDTg 
amylin receptor activation, meal patterns were analyzed (n=5). Unilateral injection of sCT 
in the LDTg at doses effective for reducing overall intake (0, 0.01, 0.04, or 0.1µg) 
significantly suppresses meal size 24h after injection (F3,15=5.18, p<0.01; Figure 3A).  
Post-hoc analyses reveal that administration of the two highest doses, 0.04 and 0.1 µg 
sCT, significantly decreases meal size compared to aCSF treatment (p<0.05), consistent 
with the established role of amylin as a satiation signal (Lutz, 2012; Mietlicki-Baase et 
al., 2013a; Mietlicki-Baase et al., 2015b). Along with this suppression in meal size, intra-
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LDTg administration of sCT also reduces meal duration at all doses tested (F3,15=5.51, 
p<0.01; p<0.05, compared to aCSF treatment; Figure 3B). LDTg amylin receptor 
activation increases latency to first meal (F3,15=4.90, p<0.05; Figure 3C) at the highest 
dose (p<0.05, compared to aCSF treatment), which indicates a decreased motivation to 
initiate feeding. Intra-LDTg administration of sCT decreases meal number over 24h after 
injection (F3,15≥3.77, p<0.05: Figure 3D), but only with the highest dose, 0.1 µg sCT 
(p<0.05, compared to aCSF treatment). These data show that LDTg amylin receptor 
activation reduces food intake predominately via suppression of meal size rather than 
meal number. Importantly, this reduction in meal size is concomitant with a decrease in 
meal duration, which may be a consequence of reduced within-meal motivation to 
continue to feed and/or reflect the normal physiological characteristics of amylin’s effects 
on the behavioral satiation sequence. 
LDTg amylin receptor activation attenuates motivation for a palatable food 
 Given that the LDTg is a reward-relevant nucleus (Schmidt et al., 2009; Dickson 
et al., 2011), we next tested the hypothesis that LDTg amylin receptor activation 
attenuates motivated feeding as measured by sucrose self-administration on a 
progressive ratio (PR) schedule of reinforcement (n=8). Unilateral injection of either the 
native peptide amylin (0.4µg) or amylin receptor agonist sCT (0.04 µg) into the LDTg 
significantly suppresses active lever responses for sucrose (F2,14=11.52, p<0.01: Figure 
4A), breakpoint (F2,14=11.26, p<0.01: Figure 4B), and sucrose pellets earned (F2,14=7.72, 
p<0.01; Figure 4C) compared to aCSF treatment. Notably, there is no difference 
between treatments on inactive lever responding (F2,14=1.13, p=0.35; Figure 4A). These 
data indicate that LDTg amylin receptor activation, both with the potent amylin receptor 
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agonist, sCT, and the native ligand, amylin, reduces motivation to self-administer a 
palatable food (i.e. sucrose). 
LDTg amylin receptor activation does not produce malaise 
 To determine if nausea/malaise contributes to the intake suppression following 
central amylin receptor activation, pica was measured after intra-LDTg sCT 
administration. Pica is the ingestion of non-nutritive substances, such as kaolin clay, and 
is a well-established model for nausea/malaise in non-vomiting species such as the rat 
(Mitchell et al., 1977; Takeda et al., 1993; Yamamoto et al., 2002; Andrews and Horn, 
2006; Kanoski et al., 2012a). The same doses of sCT used in the previous behavioral 
studies (0, 0.01, 0.04, or 0.1µg) were injected unilaterally in the LDTg, and intakes of 
chow and kaolin clay were measured 24h after injection (n=6). Intra-LDTg sCT does not 
increase kaolin intake at any dose (F3,15=0.98, p=0.45; Figure 4D), but all three doses 
significantly suppress chow intake at 24h compared to aCSF treatment (F3,15=7.93, 
p<0.01; post-hoc test, p<0.05, Figure 4E). These data suggest that the hypophagia and 
decreased motivation to feed following intra-LDTg amylin receptor activation are likely 
not due to induction of nausea/malaise. 
LDTg amylin receptor blockade attenuates the intake suppressive effects of peripheral 
amylin receptor activation 
 Given that pharmacological activation of amylin receptors directly in the LDTg 
suppresses food intake, the ability of peripherally administered amylin or amylin receptor 
agonists to access the CNS, and act specifically within the LDTg, is a key consideration 
in the development of amylin-based anti-obesity pharmaceuticals and denotes potential 
pre-clinical relevance in animal models and clinical relevance in humans. Thus, to begin 
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to address this critical question using a pre-clinical rodent model, we evaluated whether 
the intake- and body weight-suppressive effects of systemic sCT (5 µg/kg, IP) would be 
attenuated by acute LDTg amylin receptor blockade. We intentionally chose a dose of 
the amylin receptor antagonist AC187 that is subthreshold for an effect on feeding when 
delivered bilaterally within the LDTg (0.8 µg/hemisphere; n=11) so as not to have 
competing orexigenic and anorexic behavioral responses. As expected, systemic 
administration of sCT significantly suppresses cumulative chow intake at 3, 6, and 24h 
after injection (main effects of sCT, F1,10≥11.31, p<0.01; planned comparisons of 
aCSF/sCT versus aCSF/saline or AC187/saline at 3, 6, and 24h, p<0.05; Figure 5A). A 
significant interaction between sCT and AC187 occurs at 6h and 24h after injection 
(F1,10≥5.20, p<0.05); post hoc analyses reveal that pre-treatment with intra-LDTg AC187 
significantly attenuates the intake-suppressive effects of peripheral sCT at 24h (p<0.05). 
Systemic administration of sCT also decreases 24h body weight gain (F1,10=20.30, 
p<0.01, main effect of sCT; Figure 5B). Treatment with aCSF/sCT suppresses 24h body 
weight gain compared to aCSF/saline and AC187/saline conditions (planned 
comparisons, p<0.05). Importantly, amylin receptor blockade alone (AC187/saline) does 
not significantly increase chow intake at any time point (no main effects of AC187, 
F1,10<1.61, p>0.2) or body weight (no main effect of AC187, F1,10=1.56, p>0.2). These 
data show that intra-LDTg amylin receptor blockade attenuates the intake-suppressive 
effects of a systemically delivered amylin receptor agonist, suggesting the potential pre-
clinical relevance of LDTg amylin receptor signaling.  
Knockdown of calcitonin receptors in the LDTg increases chow intake and body weight  
 In order to determine if endogenous LDTg amylin receptor signaling is 
physiologically required for the normal day-to-day control of energy balance, an adeno-
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associated virus of serotype 1 (AAV1) that encodes a short hairpin RNA (shRNA) to 
knockdown CTR, the core component of the amylin receptor (AAV-CTR KD), or an 
empty vector control (AAV-Control) (Mietlicki-Baase et al., 2015b) was injected bilaterally 
into the LDTg (200nl/hemisphere). Compared to AAV-Control animals, AAV-CTR KD 
decreases LDTg CTRa expression by approximately 67% (Figure 6A, F1,10=5.43, 
p<0.05). Representative GFP visualization of viral targeting and spread from a separate 
cohort of animals sacrificed two weeks after bilateral LDTg viral injection (n=3/viral 
condition) is shown in Figure 6B. 
 Animals with LDTg amylin receptor knockdown show a sustained elevation in 
body weight compared to the AAV-Control rats (Figure 6C). ANOVAs show that AAV-
CTR KD animals weigh more than AAV-Control animals, either approaching (F1,12≥3.30, 
p<0.1) or reaching (F1,12≥4.75, p<0.05) statistical significance on any given experimental 
test day, beginning 3 days after viral injection. When analyzed as cumulative body 
weight gain from D0 to D31, AAV-CTR KD produces a significant increase in body 
weight gain compared to AAV-Control (F1,12=4.73, p=0.050; Figure 6E).   
 AAV-CTR KD treatment causes small increases in 48h binned food intake 
(Figure 6D). ANOVAs show that AAV-CTR KD animals eat significantly more in 48h bins 
than AAV-Control animals on days 7-9 and 29-31 (F1,12≥5.78, p<0.05), with a trend for 
significance (F1,12≥3.50, p<0.1) on days 1-3, 9-11, and 19-21. When graphed 
cumulatively from day 0 to day 31, AAV-CTR KD rats have a trend for increased 
cumulative intake compared to AAV-Control rats (F1,12=3.92, p<0.1; Figure 6F).  
Together, these data show that endogenous amylin accesses the LDTg and establish a 
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physiological role for LDTg amylin receptor signaling in the normal control of food intake 
and body weight regulation. 
LDTg amylin receptors are expressed on GABAergic neurons 
 Next, we performed immunohistochemistry to determine the phenotype of amylin 
receptor-expressing cells in the LDTg. Sections were labeled for the amylin receptor 
(CTR), NeuN (a neuronal marker), and GFAP (a glia/astrocyte marker). CTR expressing 
cells in the LDTg co-localize exclusively with NeuN (Figure 7A), suggesting that amylin 
receptor-expressing cells in the LDTg are primarily, if not exclusively, neuronal (n=3).  
To begin to evaluate the phenotype of LDTg CTR-expressing neurons, further 
IHC experiments tested if the CTR-positive neurons within the LDTg are cholinergic or 
GABAergic, as these represent classic LDTg neurotransmitter phenotypes (Wang and 
Morales, 2009). Results indicate that CTR in the LDTg does not co-localize with ChAT, a 
marker for cholinergic neurons (Figure 7B; n=6). After colchicine treatment (Wang et al., 
2014), 13.7% of CTR neurons in the LDTg, specifically in the caudal LDTg (-8.6mm to -
9.1mm from bregma) co-localize with the GABAergic neuronal marker, Gad67 (Figure 
7C; n=1). These data suggest that at least a portion of amylin receptor-expressing cells 
in the LDTg are GABAergic neurons, though we cannot rule out the possibility that 
colchicine treatment did not result in labeling of all Gad67 cells.  
Intra-LDTg GABA-A/B receptor blockade reverses the intake-suppressive effects of 
LDTg amylin receptor activation 
 As our data show that LDTg amylin receptor signaling regulates food intake and 
body weight, and that a portion of LDTg amylin receptor-expressing cells are 
GABAergic, we next evaluated the hypothesis that LDTg GABA receptor signaling is 
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downstream of LDTg amylin receptor activation and mediates LDTg amylin-induced 
hypophagia. To test this hypothesis, a cocktail composed of the GABA-A receptor 
antagonist bicuculline (100 ng) and the GABA-B receptor antagonist saclofen (500 ng) 
was unilaterally injected in the LDTg at doses subthrehold for an effect on feeding (100 
nl, 50% DMSO in aCSF) followed by a unilateral injection of sCT (0.04µg; 100 nl, aCSF 
vehicle) in the ipsilateral LDTg; subsequent chow intake and body weight change were 
measured (n=8).  
For cumulative chow intake (Figure 8A), repeated measures ANOVAs show a 
significant main effect of sCT at all timepoints (F1,7≥8.30, p<0.05) and a significant main 
interaction between sCT and GABA receptor blockade at 24h after injection (F1,7=7.47, 
p<0.05). Specifically, chow intake following 50% DMSO/sCT is significantly suppressed 
at 1 and 24h after injection, compared to all other conditions (planned comparisons, 
p<0.05). Importantly, intra-LDTg GABA-A/B receptor blockade does not affect feeding on 
its own (F1,7<4.70, p>0.1), but reverses the intake-suppressive effects of intra-LDTg sCT 
at 24h after injection (GABA-A/B receptor antagonists/sCT versus 50% DMSO/sCT, 
p<0.05; versus 50% DMSO/aCSF, p>0.4). Based on the feeding data, we analyzed the 
body weight change (Figure 8B) as a one-way repeated measures ANOVA by treatment 
(F3,21=7.77, p<0.01). Body weight gain following 50% DMSO/sCT treatment is 
significantly suppressed compared to all other treatments (p<0.01). Importantly, GABA 
receptor blockade alone (GABA-A/B receptor antagonists/aCSF) does not significantly 
alter body weight (p>0.9) compared to 50% DMSO/aCSF treatment. These data show 
that intra-LDTg GABA-A/B receptor blockade attenuates the anorexia produced by an 
intra-LDTg amylin receptor agonist. 
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Discussion 
 The current obesity epidemic (Ogden et al., 2012) highlights the urgent need to 
understand the neuroendocrine signals and neurobiological substrates that regulate 
energy balance, which in turn will inform the identification of novel opportunities for 
obesity pharmacotherapies. Recent attention has focused on targeting the amylin 
system for treating obesity, as the amylin analogue pramlintide is FDA-approved for 
diabetes and also decreases food intake and body weight in obese patients (Edelman et 
al., 2008; Halford et al., 2010). Although research on amylin’s effects on energy balance 
has predominately focused on hindbrain and hypothalamic structures [see (Rushing, 
2003; Lutz, 2012; Mietlicki-Baase and Hayes, 2014) for review], in vitro radiography data 
show amylin binding sites are found throughout the brain (Sexton et al., 1994), 
suggesting the likelihood of more distributed effects. The LDTg of the caudal midbrain 
represents one such amylin binding site; this nucleus receives information from and 
projects to several hindbrain, midbrain, and forebrain structures important for food 
intake, body weight regulation, and reward (Cornwall et al., 1990). Our experiments here 
show that the components of the amylin receptor complex are expressed in the LDTg 
and that amylin receptor signaling in the LDTg is important for the control of food intake 
and body weight regulation. Additionally, our data identify a portion of LDTg amylin 
receptor-expressing cells as GABAergic neurons that we speculate may be 
interneurons. These findings highlight the LDTg as a potential energy balance hub and 
show that this nucleus is of potential pre-clinical relevance as a neural substrate that can 
be targeted for future amylin-based pharmacotherapies for obesity.  
 Despite the fact that the LDTg receives information from and projects to a 
number of feeding- and reward-relevant nuclei throughout the brain (Cornwall et al., 
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1990) and expresses receptors for a variety of feeding peptides (e.g. amylin, ghrelin, 
glucagon-like peptide-1, peptide YY) (Merchenthaler et al., 1999; Parker and Herzog, 
1999; Dickson et al., 2011; Cabral et al., 2013), little attention has been paid to this 
nucleus for its role in energy balance control. The current data showing that LDTg amylin 
receptor activation suppresses food intake and body weight is highly novel and 
consistent with the satiating properties following systemic or intracerebroventricular 
administration of amylin [see (Lutz, 2012; Hayes et al., 2014a) for review]. Importantly, 
the suppression in food intake by LDTg amylin receptor activation is not likely due to 
nausea/malaise as LDTg amylin receptor activation does not produce pica, suggesting 
the specificity of the energy balance effects. Two additional explanations underlying the 
body weight changes following LDTg amylin receptor activation are decreases in 
intestinal food weight and/or reductions in prandial drinking. Future studies should 
examine whether LDTg amylin signaling directly impacts fluid intake in the absence of 
food, as well as any potential effects on intestinal food weight. The aforementioned 
experiments utilize the amylin receptor agonist sCT, which binds irreversibly with high 
affinity to amylin receptors but also with low affinity to calcitonin receptors (Christopoulos 
et al., 1999; Lutz et al., 2000; Tilakaratne et al., 2000). In contrast, amylin itself binds 
with moderate affinity to amylin receptors and with very low affinity to calcitonin 
receptors (Christopoulos et al., 1999; Morfis et al., 2008). Furthermore, while we show 
evidence of gene expression of the amylin receptor complex in the LDTg, it is important 
to point out that the qPCR micropunch data cannot establish whether both components 
of the amylin receptor are expressed in the same cell. However, given that intra-LDTg 
amylin administration suppresses food intake and body weight in a dose-dependent 
manner, the collective body of data presented here suggest that complete amylin 
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receptors are likely expressed in the LDTg and amylin receptor signaling is likely 
mediating the observed hypophagic response. 
The within-meal intake inhibitory effects of LDTg amylin signaling may be 
explained by a reduction in the rewarding value of the ongoing meal. Indeed, we show 
that LDTg amylin receptor activation not only suppresses the size of the meal, but also 
produces a concomitant decrease in meal duration, as well as a decrease in motivation 
to work for a palatable sucrose reward. The LDTg is reciprocally connected to both the 
NTS and VTA (Cornwall et al., 1990). Given the role of the NTS in meal size control [see 
(Moran, 2009; Grill and Hayes, 2012) for review] and the VTA in reward processing [see 
(Narayanan et al., 2010; DiLeone et al., 2012) for review], the suppression of meal size 
observed after LDTg amylin receptor activation likely involves amylinergic modulation of 
NTS-LDTg-VTA neural processing. However, future systematic neuroanatomical studies 
are needed to confirm that amylin receptor-expressing LDTg neurons impinge on this 
proposed NTS-LDTg-VTA circuitry through putative LDTg GABAergic inhibition of the 
NTS-LDTg-VTA polysynaptic communication. Alternatively, the decreased PR 
responding may be a secondary response to LDTg amylin receptor signaling inducing 
satiation signaling more generally and potentially independent of reward signaling. 
Previous studies have established a role for the LDTg in reward processing for 
drugs of abuse and natural rewards (e.g. food, sex) through modulation of VTA 
dopaminergic cell firing (Floody and Cramer, 1986; Lodge and Grace, 2006; Schmidt et 
al., 2009; Dickson et al., 2011; Steidl et al., 2015). Our findings extend this literature on 
the role of the LDTg in modulating feeding behavior and energy balance, and provide 
novel evidence to suggest that LDTg signaling modulates the rewarding value of the 
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ongoing meal. Given that activation of a LDTg-VTA pathway and its downstream targets 
can promote feeding and reward-associated behaviors, such as conditioned place 
preference and cocaine seeking (Schmidt et al., 2009; Dickson et al., 2010; Dickson et 
al., 2011; Jerlhag et al., 2012; Lammel et al., 2012), amylin receptor activation of 
inhibitory GABA neurons in the LDTg may decrease VTA dopaminergic cell firing, 
ultimately leading to hypophagia and a reduction in motivated feeding. Our IHC and 
behavioral data provide converging evidence in support of this hypothesis. We speculate 
that LDTg amylin receptors may be expressed on putative GABAergic interneurons, 
suggesting that LDTg amylin receptor activation could result in local inhibition of a 
variety of output neural pathways, including those projecting to the VTA. Future studies 
should therefore examine whether LDTg amylin receptor activation suppresses VTA 
dopaminergic cell activity in response to a food reward, and whether this outcome is in 
fact LDTg-GABA mediated.  
 Arguably one of the most important findings from the current data set is that 
acute blockade of LDTg amylin receptors attenuates the intake-suppressive effects of a 
systemic amylin receptor agonist. Though a significant attenuation of the intake-
suppressive effects is not observed until the 24h timepoint, these data are comparable to 
a similar experiment performed in the VTA (Mietlicki-Baase et al., 2013b) in which 
effects were also only observed at 24h. In contrast to the VTA and LDTg, previous 
reports have shown that systemically delivered amylin agonists are able to activate AP 
amylin receptors more rapidly (Roth et al., 2009; Mietlicki-Baase and Hayes, 2014). 
Thus, there appears to be a temporal difference in systemic amylin agonists’ action in 
distributed nuclei throughout the neuraxis that requires further investigation. 
Nevertheless, the data suggest that amylin receptor agonists administered systemically 
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can access the LDTg, and thus LDTg amylin receptors may represent a pre-clinically 
relevant CNS population that can be targeted by peripherally-administered amylin 
receptor ligands for the treatment of obesity. Importantly, the dose of AC187 utilized 
here was selected to be subthreshold for an effect on food intake when administered in 
the LDTg. However, future experiments should utilize different doses of AC187 on its 
own in the LDTg to examine the effect of endogenous amylin on food intake, body 
weight, and motivated behavior in acute studies.  Furthermore, the longer-term 
physiological role of LDTg amylin receptor signaling for energy balance control is 
supported by our study examining the effects of LDTg amylin receptor knockdown. 
Virogenetic knockdown of LDTg CTR increased body weight and food intake, suggesting 
that endogenous amylin can access the LDTg and that LDTg amylin receptors exert 
chronic control over energy balance. Interestingly, binned increases in food intake were 
modest compared to binned increases in body weight, suggesting an unexplored 
contribution of decreased energy expenditure following LDTg amylin receptor 
knockdown. Therefore, future experiments should examine how amylin signaling in the 
LDTg affects energy expenditure.  
 The novel findings here support the hypothesis that amylin receptor signaling in 
the LDTg is important for food intake and body weight regulation. These data highlight 
the importance of focusing further attention on this understudied nucleus in the field of 
obesity research. We have identified a subset of amylin receptor expressing cells in the 
LDTg are GABAergic neurons, which allows for future dissection of the downstream 
neurons and nuclei that are presumably inhibited by LDTg amylin receptor activation. As 
the LDTg also expresses receptors for other energy balance-relevant hormones 
(Merchenthaler et al., 1999; Parker and Herzog, 1999; Dickson et al., 2011; Cabral et al., 
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2013), future studies should explore how amylin signaling in the LDTg potentially 
interacts with other feeding-related signals to exert integrated control of energy balance 
and food reward. 
  
 
105 
	
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The components of the amylin receptor complex are expressed in the 
LDTg. Micropunches of LDTg-enriched tissue (n=6) show expression that gene 
expression of CTRa is ~5 fold higher than CTRb (A), and gene expression of RAMP1 is 
~2-fold higher than RAMP2 and ~13-fold higher than RAMP3 (B). Immunohistochemical 
data using CTR to label amylin receptor-expressing cells (n=6) show dense labeling of 
cell bodies and projections in the caudal LDTg (C, D). The dotted box in C (20x) 
represents the field of view in D (20x with a 2x optical zoom). * indicates significance by 
repeated measures ANOVA (p<0.05). 
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Figure 2. Intra-LDTg amylin receptor activation dose dependently suppresses 
chow intake and body weight. Amylin was unilaterally injected into the LDTg in a 
counterbalanced within-subjects design at the onset of the dark cycle using the following 
doses: 0 (aCSF), 0.2, 0.4, and 0.8 µg (n=10). A representative image of the LDTg 
injection site from a 35 µm thick section is shown (A). These doses of amylin dose-
dependently decrease chow intake over 6h but have no effect on 24h chow intake (B) or 
body weight change (C). The key in B also applies to C. In a separate cohort of rats, the 
amylin receptor agonist sCT was unilaterally injected into the LDTg in a counterbalanced 
within subjects design at the onset of the dark cycle using the following doses: 0 (aCSF), 
0.01, 0.04, and 0.1 µg (n=6). These doses of sCT suppress chow intake at every time 
point tested over 24h (D) and decrease 24h body weight gain (E).   * indicates 
significance by repeated measures ANOVA (p<0.05), # indicates a trend for significance 
by post-hoc Neuman-Keuls (p<0.1). Different letters are significantly different from each 
other (p<0.05) according to post-hoc tests. The key in D also applies to E. Atlas image is 
-8.7 mm from bregma, based on Paxinos & Watson, 2007. 4V = 4th ventricle, CIC = 
central nucleus inferior colliculus, DTgP = Dorsal tegmental nucleus pericent, LDTg= 
lateral dorsal tegmental nucleus, LPAG = lateral periaqueductal gray, mlf = medial 
longitudinal fasciculus, VLPAG = ventral lateral periaqueductal gray. 
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Figure 3. Intra-LDTg amylin receptor activation predominately suppresses meal 
size rather than meal frequency. To determine the behavioral mechanism driving 
intake suppression, animals were housed in a custom-made automated feedometer to 
analyze meal patterns. The amylin receptor agonist, sCT, was unilaterally injected into 
the LDTg in a counterbalanced within subjects design at the onset of the dark cycle 
using the following doses: 0 (aCSF), 0.01, 0.04, and 0.1 µg (n=5). Intra-LDTg sCT 
suppresses meal size over 24h at the two higher doses (A), but all 3 doses suppress 
average meal duration over 24h (B). Only the highest dose of sCT increases latency to 
first meal (C) and suppresses meal frequency over 24h (D). The key applies to all 
graphs. * indicates significance by repeated measures ANOVA (p<0.05), different letters 
are significantly different from each other according to post-hoc tests (p<0.05).  
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Figure 4. Intra-LDTg amylin receptor activation suppresses motivated feeding but 
does not produce malaise. The ability of LDTg amylin receptor activation to reduce 
sucrose self-administration on a PR schedule of reinforcement was assessed (n=8). 
Intra-LDTg amylin receptor activation with amylin (0.4µg) or sCT (0.04µg) suppresses 
active lever presses (A), breakpoint (B), and pellets earned (C). To determine if LDTg 
amylin receptor activation produces nausea/malaise, pica (ingestion of non-nutritive 
substances in response to a noxious stimulus) was measured. Animals received access 
to both chow and kaolin clay for one week prior to the beginning of the experiment. The 
amylin receptor agonist, sCT, was unilaterally injected into the LDTg using the following 
doses: 0 (aCSF), 0.01, 0.04, and 0.1 µg (n=6). Intra-LDTg amylin receptor activation 
does not increase kaolin clay intake (D) but suppresses chow intake at 24h (E). Key in A 
applies to A, B and C; key in D applies to D and E. * indicates significance by repeated 
measures ANOVA (p<0.01); different letters are significantly different from each other 
according to post-hoc tests (p<0.05). 
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Figure 5. LDTg amylin receptor blockade attenuates the intake suppressive effects 
of an amylin receptor agonist. To determine if LDTg amylin receptor signaling is pre-
clinically relevant, the amylin receptor antagonist, AC187, was bilaterally injected in the 
LDTg (0.8µg/hemisphere) followed 45 minutes later by a systemic injection of sCT 
(5µg/kg, IP) shortly before the onset of the dark cycle (n=11). Pre-treatment of AC187 
alone has no significant effect on chow intake or body weight at any time point. 
Administration of sCT significantly suppresses intake at 3, 6, and 24h (A) as well as 24h 
body weight gain (B). Pre-treatment of AC187 with sCT significantly attenuates the 
intake suppressive effects of systemically-delivered sCT. Legend applies to both graphs. 
* indicates a significant main effect of sCT by repeated measures ANOVA (p<0.01), Ŧ 
indicates a significant main interaction between sCT and AC187 by repeated measures 
ANOVA (p<0.05), and different letters are significantly different from each other 
according to post-hoc planned comparisons (p<0.05). 
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Figure 6. CTR knockdown in the LDTg produces sustained increases in body 
weight and chow intake. To determine if LDTg amylin receptor signaling is 
physiologically relevant for the long-term control of food intake and body weight 
regulation, an AAV that knocks down the core component of the amylin receptor, the 
CTR (AAV-CTR KD), or an empty vector AAV (AAV-Control) was injected bilaterally in 
the LDTg (200nl/hemisphere). Food intake and body weight was measured every 48h for 
31 days following viral injection (n=7/viral condition). (A) Compared to AAV-Control, the 
AAV-CTR KD produces a statistically significant 67% decrease of CTRa. A separate 
cohort of animals received either virus (n=3/viral condition), were sacrificed two weeks 
later, and the brains were processed for GFP visualization. Representative images show 
GFP labeling of viral expression in AAV-Control (left) and AAV-CTR KD (right) (B). In 
behavioral studies, AAV-CTR KD produces an increase in body weight that was 
sustained over the behavioral test period (C, E).  Chow intake is transiently increased in 
AAV-CTR KD animals compared to AAV-Control animals when graphed in 48 bins (D), 
and trending for significance when graphed cumulatively over the entire behavioral test 
period (F, p<0.1). * indicates significance by ANOVA (p≤0.050), # indicates a trend for 
significance by ANOVA (p<0.1). 4V = 4th ventricle, DTPg = Dorsal tegmental nucleus 
pericent, LDTg= lateral dorsal tegmental nucleus, LDTgV = lateral dorsal tegmental 
nucleus ventral, mlf = medial longitudinal fasciculus, SPTg = subpeducuncular tegmental 
nucleus, VLPAG = ventral lateral periaqueductal gray. 
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Figure 7. CTR-expressing cells in the LDTg are GABAergic. IHC analyses show that 
CTR-expressing cells in the LDTg co-localize with the neuronal marker NeuN and not 
with the glial cell marker GFAP (A; 20x with a 2x optical zoom; n=3). CTR-expressing 
cells in the LDTg do not co-localize with the cholinergic marker ChAT (B; 40x; n=6) but 
co-localize with the GABAergic marker Gad67 (C; 20x; n=1). Red = CTR-positive cells; 
Blue = GFAP-positive cells; Green = cellular marker of interest: NeuN (A), ChAT (B), 
Gad67 (C). White arrows indicate co-localization. 
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Figure 8. Intra-LDTg GABA receptor blockade reverses the intake suppressive 
effects of intra-LDTg amylin receptor activation. To determine the role of GABA 
receptor signaling in the intake suppressive effects of LDTg amylin receptor activation, a 
cocktail of a GABA-A receptor antagonist (bicuculline, 100 ng) and a GABA-B receptor 
antagonist (saclofen, 500 ng) was administered unilaterally in the LDTg followed by sCT 
(0.04µg; 100 nl; n=8). GABA receptor blockade reverses the intake (A) and body weight-
suppressive effects (B). Key applies to both graphs. * indicates a significant main effect 
of sCT (A) or treatment (B) by repeated measures ANOVA (p<0.05), Ŧ indicates a 
significant main interaction between sCT and the GABA-receptor antagonists by 
repeated measures ANOVA (p<0.05), different letters are significantly different from 
each other according to post-hoc planned comparisons (p<0.05).  
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CHAPTER 5: GENERAL DISCUSSION AND CONCLUSION 
 There is a critical need for basic science research to identify key neurochemical 
systems that can be targeted by current and future pharmacotherapies aimed at treating 
obesity and its associated metabolic co-morbidities. To this end, identifying the site(s) of 
action (e.g. cellular and nuclei specificity) of endogenous energy balance signals and 
long-acting clinically relevant receptor agonists is paramount in treating human obesity. 
The data presented in this dissertation provide evidence that GLP-1Rs expressed on 
astrocytes in the NTS are relevant for energy balance control and that GLP-1 and amylin 
individually act in the LDTg to control energy balance. As a whole, these data broaden 
the view of CNS actions of GLP-1 and amylin, in terms of both the cellular and regional 
control of energy balance. In this chapter, I summarize key findings, discuss questions 
these data raise, and propose future avenues of research. 
What is the purpose of astrocytic expression of GLP-1R? 
 Data presented in Chapter 2 show that NTS astrocytes express GLP-1Rs, 
respond appropriately to GLP-1R activation with increases in intracellular calcium and 
cAMP, and are behaviorally relevant for energy balance control. These findings are part 
of a growing body of literature showing that astrocytes respond to energy status signals 
and contribute to energy balance control [see (Kim et al., 2014; Wang et al., 2015; Frago 
and Chowen, 2017) for review]. These data establish a novel role for NTS astrocytes in 
GLP-1R signaling and energy balance control more broadly, but the biological function of 
NTS astrocytes needs to be investigated.  
These data raise the natural question of the biological/physiological purpose of 
GLP-1R signaling in NTS astrocytes in coordinating energy balance control. As 
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presented in Chapter 2, one potential source of GLP-1 to NTS astrocytes is from PPG 
neurons within the NTS, indicated by triple labeling of GLP-1, GFAP, and synaptophysin. 
It is likely that astrocytes form a tripartite synapse with NTS neurons, though the precise 
structure and dynamics of this putative neuron-glia interaction for GLP-1R signaling 
needs to be further investigated. Future research should include ultrastructure analyses 
with electron microscopy to examine the putative tripartite synapse between neurons 
and GLP-1R-expressing astrocytes. Following GLP-1R activation, research has shown 
increases in intracellular calcium and cAMP, PKA and MAPK activation, and 
downregulation of AMPK (Perfetti and Merkel, 2000; Gomez et al., 2002; Hayes et al., 
2011b). However, when studies using tissue lysates to examine GLP-1R signaling 
results cannot distinguish between cell types. While data presented in Chapter 2 show 
increases in intracellular calcium in both astrocytes and neurons following bath 
application of Ex-4, the magnitude of response is greater in astrocytes than neurons, 
suggesting that there may be unexplored cell type-dependent differences in downstream 
cell signaling cascades. It is therefore critically important to first determine the separate 
intracellular signaling cascades after GLP-1R activation in astrocytes versus neurons 
(e.g. with cultured astrocytes and cultured neurons) and then to determine whether the 
responses vary when astrocytes and neurons are expressed together (e.g. in co-cultures 
of both cell types).  As modern techniques allow for visualization of calcium dynamics in 
vivo in awake behaving animals (Akerboom et al., 2012; Gee et al., 2015; Srinivasan et 
al., 2016), future experiments could measure calcium in NTS astrocytes and neurons 
from awake, behaving animals in response to a variety of stimuli (daily meals, systemic 
or central GLP-1R activation, exogenous administration of energy status signals, gastric 
distension, etc.). Furthermore, this technique has the potential to provide a holistic view 
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of the role of astrocytes in energy balance control, by allowing for the analysis of calcium 
dynamics within astrocytes throughout the CNS after administration of energy status 
signals (e.g. GLP-1, amylin, leptin, ghrelin, etc.), with diet manipulations, or as a function 
of state (e.g. fed vs fasted, lean vs obese). Collectively, data in Chapter 2 establish a 
role for NTS astrocytes in GLP-1-mediated energy balance control, suggesting that 
astrocytes likely interact with neurons as part of a tripartite synapse in the NTS to 
respond to the environment and contribute to energy balance control. 
Given that a predominant role of astrocytes within a tripartite synapse is the 
regulation of synaptic glutamate levels (Perego et al., 2000; Rimmele and Rosenberg, 
2016), could GLP-1R-expressing NTS astrocytes modulate glutamate levels and if so, 
how might that affect food intake? As part of the canonical signaling pathway following 
GLP-1R activation, PKA levels increase (Hayes et al., 2011b; Rupprecht et al., 2013), 
and separately, PKA can modulate expression of glutamate transporters (Lim et al., 
2005). We hypothesize that GLP-1R activation in NTS astrocytes decreases glutamate 
transporter expression, which would thereby increase the level of synaptic and 
extrasynaptic glutamate. Elevated glutamate levels would then putatively lead to 
downstream activation of AMPA and NMDA receptors, which have been shown to 
mediate GLP-1R-dependent suppression of food intake (Hisadome et al., 2011; Mietlicki-
Baase et al., 2013a; Mietlicki-Baase et al., 2014). Therefore, the expression of NTS 
glutamate transporters (GLT-1 and GLAST) should be evaluated in a time-specific 
manner following GLP-1R activation, and the role of potential changes in glutamate 
transporter expression in GLP-1R-mediated suppression of food intake should be 
functionally tested (e.g. with ceftriaxone, a GLT-1 upregulator). If our hypothesis is 
correct and GLP-1R activation decreases glutamate transporter expression, 
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administration of ceftriaxone should attenuate or reverse GLP-1-mediated hypophagia 
by increasing GLT-1 expression.  
In addition to modulating synaptic glutamatergic signaling, following chemical 
activation and through a calcium-dependent process, astrocytes within a tripartite 
synapse can release gliotransmitters (Nedergaard et al., 2003; Ransom et al., 2003; 
Halassa et al., 2007; Barres, 2008; Eroglu and Barres, 2010; Clarke and Barres, 2013; 
Robinson and Jackson, 2016). Given that the live cell calcium imaging data in Chapter 2 
show a robust increase in intracellular calcium in NTS astrocytes following bath 
application of Ex-4, it is possible that GLP-1R mediated activation of astrocytes may 
stimulate the release of gliotransmitters. The role of gliotransmission should therefore be 
functionally tested with pharmacology, for example by probing the response to GLP-1R 
activation in an astrocyte-specific dominant negative Soluble N-ethylmaleimide-sensitive 
factor activation protein receptor (SNARE) animal, in which gliotransmission is 
genetically prevented. Collectively, data presented in Chapter 2 provides evidence in 
support of the importance of NTS astrocytes in GLP-1R-mediated energy balance 
control, and also sets the foundation for further investigation of the functional role of NTS 
astrocytes in modulating neuronal activity to control energy balance. 
Data presented in Chapter 2 showing that NTS astrocytes can bind peripherally 
administered GLP-1R agonists is consistent with the idea that astrocytes can sense 
blood-borne factors (Yi et al., 2011; Chowen et al., 2016; Leloup et al., 2016; Argente-
Arizon et al., 2017), These data support a growing body of evidence that the NTS is a 
critical site in mediating GLP-1R activation and provide further evidence that this nucleus 
is potentially clinically relevant for GLP-1R-mediated energy balance control (Hayes et 
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al., 2008; Grill and Hayes, 2009; Hayes et al., 2011a; Hayes et al., 2011b; Grill and 
Hayes, 2012; Rupprecht et al., 2013; Alhadeff and Grill, 2014; Alhadeff et al., 2016). In 
addition to sensing blood-borne factors, astrocytes can modulate the permeability of the 
blood brain barrier (BBB) through associations with endothelial cells and release of 
chemical factors (Abbott et al., 2006). One intriguing avenue of research would be to 
examine astrocytic modulation of BBB permeability and determine whether CNS 
penetrance of neuroendocrine signals (e.g. GLP-1, amylin) changes based on state of 
the animal (fed vs. fasted, lean vs. obese, male vs. female). If BBB permeability 
deteriorates in the obese state, leading to altered endogenous gut-brain signaling, could 
improved constructs of neuroendocrine receptor agonists result in increased BBB 
penetrance and normalize central energy balance control? Alternatively, would targeting 
astrocytes/endothelial cells improve BBB penetrance and lead to a restoration of 
endogenous gut-brain signaling in the obese state? Collectively, the data presented in 
Chapter 2 invoke these important and clinically-relevant questions regarding BBB 
penetrance of energy status signals and how astrocytes might be therapeutic targets to 
modulate BBB permeability. 
Importantly, NTS astrocytic expression of GLP-1R raises the question of whether 
GLP-1R are expressed on astrocytes in other nuclei important for energy balance and 
reward. For example, data in Chapter 3 shows that fluorescent exendin-4 associates 
with predominately neurons and minimally with astrocytes in the LDTg, contrary to the 
findings in Chapter 2, which show internalization in both cell types in the NTS. These 
data in the NTS and LDTg raise the question of how cell type-specific expression of 
GLP-1R changes depending on the nuclei examined. The GLP-1 field is stymied by the 
lack of a commercially available GLP-1R-specific antibody. Therefore, there is great 
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utility for the commercially available fluorescently-labeled exendin-4 used in these 
studies to label GLP-1R-expressing cells, which will allow for determination of cell-type 
expression of GLP-1R in nuclei throughout the brain. Having this proxy to identify GLP-
1R-expressing cells in the rat and across species should be an advantageous tool for 
many researchers in the field and is already being used by other laboratories (Terrill et 
al., 2016).  
The data in Chapter 2 show fluorescent exendin-4 labeling within cells, 
suggesting that the exendin-4 and theoretically the GLP-1R are internalized in the NTS 
at 3h post-injection. To our knowledge, we are the first to provide in vivo evidence of 
GLP-1R internalization and our data are in agreement with in vitro data showing GLP-1R 
are internalized following activation in vitro (Roed et al., 2014; Shaaban et al., 2016). In 
vitro data show that the GLP-1R is internalized shortly after exposure to GLP-1 or GLP-
1R agonists (e.g. minutes), and eventually is recycled back to the cell membrane (takes 
2-3 times longer for exendin-4 and liraglutide compared to GLP-1) (Roed et al., 2014). 
However, the purpose of this internalization in neural tissue or brain-derived primary cell 
cultures has not been established. The use of fluorescent GLP-1R agonists provides the 
exciting possibility to visualize and track GLP-1 binding, activation, and internalization in 
real time with live cell imaging in in vitro and potentially ex vivo preparations in order to 
examine cell-type differences in the dynamics of cellular activation of GLP-1Rs. 
While data presented in Chapter 2 suggest that GLP-1Rs are expressed on NTS 
astrocytes in the rat, data in the literature has revealed an absence of astrocytic 
expression of GLP-1R in the mouse (Cork et al., 2015). These data are part of a small 
body of literature describing species differences in the GLP-1 system between mice, 
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rats, non-human primates, and humans (Lachey et al., 2005; Vrang and Grove, 2011; 
Cork et al., 2015; Heppner et al., 2015). The biology and physiology of the GLP-1 
system in rats seems to mimic that of non-human primates and humans more closely 
than in mice, making rats the appropriate animal model for this dissertation (Lachey et 
al., 2005; Vrang and Grove, 2011; Cork et al., 2015; Heppner et al., 2015). Given these 
data, astrocytic GLP-1R expression might extend to higher order species beyond the rat, 
but this should be empirically tested. 
Collectively, data presented in Chapter 2 establish novel cell-type dependent 
effects for GLP-1R activation in modulating energy balance and emphasize the 
importance of studying the contribution of astrocytes to energy balance control. This 
underscores the need to evaluate novel targets for GLP-1R agonists that may be 
valuable for treating obesity. In Chapters 3 and 4, the idea of examining novel potential 
targets for obesity pharmacotherapies was brought to the level of the CNS nucleus, and 
examined the relevance of the LDTg for energy balance control. 
The LDTg: an understudied hub in energy balance regulation 
 Data presented in Chapters 3 and 4 demonstrate that the LDTg responds to both 
GLP-1 and amylin to control food intake and body weight. In Chapter 3, pharmacological 
activation of LDTg GLP-1Rs decreases food intake and body weight, primarily through a 
reduction in meal size and independent of nausea/malaise. Pharmacological blockade of 
LDTg GLP-1Rs increases food intake, and a subthreshold dose of the GLP-1R 
antagonist exendin-9 administered in the LDTg attenuates the intake suppressive effects 
of peripheral exendin-4 or of a gastric pre-load. IHC data show the presence of GLP-1-
immunopositive fibers in the LDTg and that NTS PPG neurons project to the LDTg, 
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providing anatomical evidence that GLP-1R signaling in the LDTg in physiologically 
relevant. Furthermore, a peripherally administered fluorescently-labeled GLP-1R agonist 
can be visualized within the LDTg and is juxtaposed to neurons and minimally to 
astrocytes. Together, these data show that GLP-1R signaling in the LDTg contributes to 
energy balance control.  
Data presented in Chapter 4 examine another neuroendocrine system that is 
potentially clinically relevant for the treatment of obesity, amylin. Findings show that 
pharmacological activation of LDTg amylin receptors decreases food intake and body 
weight, primarily through a reduction in meal size and independent of nausea/malaise. 
Blockade of LDTg amylin receptors attenuates the intake suppressive effects of 
peripheral amylin receptor activation, while chronic knockdown of LDTg amylin receptors 
increases food intake and body weight. Furthermore, a portion of LDTg amylin receptors 
is GABAergic, and GABA receptor signaling in the LDTg is required for the hypophagic 
effects of LDTg amylin receptor activation. Together, these data show that amylin 
receptor signaling in the LDTg contributes to energy balance control.  
 Collectively, data in Chapters 3 and 4 support a role for the LDTg in processing 
neuroendocrine signals to control energy balance. These data are part of a growing 
body of literature showing that the LDTg responds to neuroendocrine signals to control 
energy balance. For example, ghrelin receptors are expressed in the LDTg, and ghrelin 
administration in the LDTg increases food intake via elevated acetylcholine release in 
the VTA and dopamine release in the NAc (Jerlhag et al., 2007; Dickson et al., 2010; 
Dickson et al., 2011; Jerlhag et al., 2012). The LDTg is clearly an energy balance-
relevant nucleus that is just beginning to be explored, though to date and including this 
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dissertation, studies have examined individual neuroendocrine signals within the LDTg 
for energy balance control. It is important to consider that the endogenous response to a 
meal includes the release of many neuroendocrine signals both from peripheral and 
central sources which can, in theory, interact in the LDTg to control energy balance. 
Indeed, the LDTg expresses a variety of receptors for neuroendocrine signals including, 
GLP-1, amylin, ghrelin, oxytocin, orexin, and PYY, and thus may integrate these signals 
to modulate energy balance (Sexton et al., 1994; Merchenthaler et al., 1999; Parker and 
Herzog, 1999; Greco and Shiromani, 2001; Gould and Zingg, 2003; Dickson et al., 2011; 
Cabral et al., 2013). 
Data in the literature support additive/synergistic effects on food intake with 
combination therapy of GLP-1 and amylin-based drugs (Bello et al., 2010). As data 
presented in this dissertation establishes a role for LDTg GLP-1R and separately LDTg 
amylin signaling for energy balance control, further investigation is needed to examine 
the potential interaction between GLP-1R signaling and amylin receptor signaling in the 
LDTg. One hypothesis is that LDTg amylin receptor signaling interacts with gut-brain 
signaling through a NTS-LDTg GLP-1 pathway. To support this hypothesis, anatomical 
data would need to show that NTS-originating GLP-1 fibers are in close apposition to 
LDTg CTR-expressing neurons and that CTR-expressing cells within the LDTg bind 
fluorescent Ex-4. These data would provide anatomical evidence that GLP-1R activation 
can enhance the effects of amylin receptor activation, potentially by acting on the same 
cell. Behavioral evidence would support this hypothesis if LDTg GLP-1R blockade 
attenuates the intake suppressive effects of LDTg amylin receptor activation.  
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In addition, the temporal dynamics of LDTg GLP-1 and amylin-mediated 
hypophagia should be explored. Data presented in Chapter 3 shows that a suppression 
in food intake is not observed until 6h after intra-LDTg Ex-4 treatment, but data 
presented in Chapter 4 shows that LDTg amylin receptor activation decreases food 
intake as early as 1h after injection. This difference in timing of intake suppression has 
also been observed in the VTA (Alhadeff et al., 2012; Mietlicki-Baase et al., 2013a; 
Mietlicki-Baase et al., 2013b; Mietlicki-Baase et al., 2015b). It is therefore important to 
examine the downstream effects of LDTg GLP-1R and amylin receptor activation and 
why temporal differences in feeding effects are observed. Are there differences in 
intracellular signaling pathways or projection patterns that would result in a slower onset 
of behavioral effects with centrally-administered Ex-4 compared to sCT or amylin? 
The interaction between orexigenic hormones (e.g. ghrelin and orexin) and 
anorexigenic hormones (e.g. GLP-1 and amylin) at the level of the LDTg remains 
unexplored. Though this dissertation focuses on two within-meal satiation signals in the 
LDTg, it is possible that the LDTg integrates pre-prandial and post-prandial release of 
energy status signals to control feeding. The precise LDTg cell types that express 
receptors for these hormones and the dynamics of how these hormones interact in the 
LDTg to potentially modulate energy balance should be explored.  
 A growing body of literature shows that the LDTg modulates VTA dopamine cell 
firing and dopamine release in the nucleus accumbens, which ultimately mediates 
motivated behavior, including food intake as well as reward behaviors and drug seeking 
(Omelchenko and Sesack, 2005; Lodge and Grace, 2006; Shabani et al., 2010; Lammel 
et al., 2012; Shinohara et al., 2014; Steidl et al., 2015; Schmidt et al., 2016; Steidl et al., 
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2017). While data presented in Chapter 3 show that peripherally-administered 
fluorescent Ex-4 is juxtaposed with neurons more so than astrocytes, these GLP-1R-
expressing LDTg neurons need to be further characterized in terms of their 
neurochemical phenotype and projection patterns. Given that a portion of LDTg amylin 
receptor-expressing neurons are GABAergic, it is possible that LDTg amylin receptor 
activation inhibits VTA dopamine neurons either through local inhibition (e.g. as an 
interneuron) of VTA-projecting cholinergic/glutamatergic LDTg neurons or through direct 
inhibition (e.g. as a projection neuron) of VTA dopamine neurons. Alternatively or 
additionally, amylin receptor expressing LDTg neurons may modulate other nuclei to 
control feeding, such as the lateral habenula or dorsal raphe, which have been 
associated with negative valence and avoidance/aversion (Matsumoto and Hikosaka, 
2009; Li et al., 2013). Neural pathway tracing coupled with immunohistochemistry will 
begin to elucidate these possibilities, both in terms of the projection patterns of GLP-1R 
and amylin receptor-expressing neurons and if GLP-1R are expressed on amylin-
receptor expressing neurons. Given the close overlap in the circuitry underlying feeding 
and addiction (Narayanan et al., 2010; DiLeone et al., 2012), these neuroanatomical 
data could have important implications not only for the field of energy balance and 
obesity, but also for the fields of motivated behavior and drug addiction. 
 In addition to effects on energy balance, GLP-1 has been shown to modulate 
other rewarding behaviors such as drug taking and seeking (Graham et al., 2013; 
Sorensen et al., 2015; Schmidt et al., 2016; Vallof et al., 2016). Though less commonly 
studied in the drug abuse field, amylin has been shown to interact with the endogenous 
opioid system and modulates the dopamine system (Clapper et al., 2013; Mietlicki-
Baase and Hayes, 2014; Mietlicki-Baase et al., 2015b). Given these findings, and that 
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GLP-1 and amylin mimetics are FDA approved for diabetes and/or obesity treatment, it 
is possible that these analogs could be repurposed to treat drug addiction. Indeed, in 
addition to effects on drug taking (Schmidt et al., 2016), exciting data from the Schmidt 
lab show that central administration of Ex-4 and separately amylin attenuates cocaine 
reinstatement, an animal model of relapse (unpublished studies). Future research in 
animal models of drug addiction and drug relapse should therefore evaluate the utility of 
GLP-1 and amylin-based pharmacotherapies for treating addiction across drug classes 
and elucidate and the CNS mechanisms by which they act.  
 One critical question raised by the data presented in Chapters 3 and 4 is how 
does the LDTg putatively integrate endogenous GLP-1R and amylin receptor signaling 
to control energy balance. One possible hypothesis is that a portion of LDTg neurons 
express both the GLP-1R and the amylin receptor and can be activated by both 
neuroendocrine signals. In this case, the onset of a meal would result in increased 
secretion of amylin by the pancreas, elevated plasma levels of amylin, and ultimately 
amylin receptor activation in the CNS, including the LDTg. As the meal continues and 
the stomach becomes further distended, NTS PPG neurons would be activated and 
theoretically increase synaptic release of GLP-1 throughout the CNS, including in the 
LDTg.  Thus, LDTg levels of amylin and GLP-1 would increase throughout the meal and 
activate LDTg neurons. However, in this scenario, there is likely a short delay (e.g. 
minutes during the meal) between when endogenous amylin and endogenous GLP-1 
accesses the LDTg, such that amylin may access the CNS first and activate LDTg 
amylin-receptor expressing neurons. LDTg neurons that express both GLP-1Rs and 
amylin receptors would be activated by both neuroendocrine signals, leading to 
sustained excitation of these neurons that perhaps are GABA neurons that project to the 
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VTA to modulate dopamine cell firing. Sustained excitation of these neurons would lead 
to an amplification of within meal satiation signaling, a decrease in the rewarding value 
of the meal, and ultimately promote for meal termination. It is also possible that there is 
also a subset of LDTg neurons that express GLP-1Rs but not amylin receptors and a 
subset of LDTg neurons that express amylin receptors but not GLP-1Rs. In addition, 
energy balance control is distributed throughout the CNS and these putative actions of 
GLP-1 and amylin within the LDTg are only representative of how one CNS nucleus 
integrates neuroendocrine signals to control energy balance. 
CONCLUSION 
 Collectively, the data presented in this dissertation broaden the perspective on 
the specific cell types and brain regions that respond to neuroendocrine signals and 
control energy balance. These data, from normal or lean male rats, provide critical 
foundational evidence for understanding the biology and physiology of the CNS and gut-
brain signaling, and also provide important knowledge for improving pharmacological 
tools to treat obesity. The ultimate goal of this information is to understand how these 
systems might be dysregulated in the obese state and how targeting multiple systems in 
a combination therapy of drugs may produce a greater magnitude of weight loss than 
individual monotherapies. The specific combination of GLP-1 and amylin-based drugs 
for obesity treatment has received attention of the past several years (Bello et al., 2010; 
Roth et al., 2012; Jorsal et al., 2016; Gydesen et al., 2017) and data presented in this 
dissertation emphasize the importance of examining both the local (cell-type) and global 
(brain-wide) effects of GLP-1 and amylin administration for potential additivity or synergy 
in decreasing food intake and promoting weight loss. 
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APPENDIX 
Figure A1. Intra-NTS GLP-1R activation in animals with missed cannula 
placements does not produce hypophagia. Rats (n=5) were given an intra-mNTS 
pretreatment with the astrocyte Krebs cycle inhibitor fluorocitrate or its vehicle, followed 
by direct mNTS administration of the GLP-1R agonist Ex-4. There is no significant main 
effect of either drug on food intake (A) or body weight (B) (F1,4<3.6, p>0.13). Data shown 
as mean ± SEM. Cannula placements are shown in C with black dots indicating cannula 
placements that accurately targeted the mNTS (SolM in C) and behavioral data from 
these animals is graphed in Figure 2.7. Red X’s indicate cannula placements that 
missed the mNTS and behavioral data from these animals is graphed here in Figure 
A1A-B. Numbers represent distance (mm) from bregma according to Paxinos & Watson 
(2007). AP = area postrema, Gr = nucleus gracilis, SolM = medial nucleus tractus 
solitarius.  
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Figure A2. Intra-LDTg GLP-1R activation in animals with missed cannula 
placements does not produce hypophagia. The GLP-1R agonist Ex-4 was unilaterally 
injected in the LDTg in a counterbalanced within-subjects design at the onset of the dark 
cycle (n=6). There is no significant main effect of drug on food intake (A) or body weight 
(B) (F1,3<0.23, p>0.80). Data shown as mean ± SEM. Cannula placements are shown in 
C with black dots indicating cannula placements that accurately targeted the LDTg and 
behavioral data from these animals is graphed in Figure 3.1C-F. Red X’s indicate 
cannula placements that missed the LDTg and behavioral data from these animals is 
graphed here in Figure A2A-B. Numbers represent distance (mm) from bregma 
according to Paxinos & Watson (2007). DRC = dorsal raphe caudal, DRD = dorsal raphe 
dorsal, LDTg = lateral dorsal tegmental nucleus, VLPAG = ventrolateral periaqueductal 
gray. 
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Figure A3. Intra-LDTg amylin receptor activation in animals with missed LDTg 
cannula placements does not cause hypophagia. The amylin receptor agonist sCT 
was unilaterally injected into the LDTg in a counterbalanced within subjects design at the 
onset of the dark cycle (n=3). There is no significant effect on food intake (A) or body 
weight (B). (F1,3<0.6, p>0.64). Data shown as mean ± SEM. Cannula placements are 
shown in C with black dots indicating cannula placements that accurately targeted the 
LDTg and behavioral data from these animals is graphed in Figure 4.3 and 4.4C-D. Red 
X’s indicate cannula placements that missed the LDTg and behavioral data from these 
animals is graphed here in Figure A3A-B. Numbers represent distance (mm) from 
bregma according to Paxinos & Watson (2007). DRD = dorsal raphe dorsal, LDTg = 
lateral dorsal tegmental nucleus, VLPAG = ventrolateral periaqueductal gray. 
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